CHARACTERIZATION OF A CHROMOSOME 11Q23 TRANSLOCATION BREAKPOINT ASSOCIATED WITH ACUTE LEUKEMIAS

Abstract: In accordance with the present invention, there is provided an isolated peptide having the characteristics of human (trithorax) protein (as well as DNA encoding same, antisense DNA derived therefrom and antagonists therefor). The invention peptide is characterized by having a DNA binding domain comprising multiple zinc fingers and at least 40 % amino acid identity with respect to the DNA binding domain of (Drosophila trithorax) protein and at least 70 % conserved sequence with respect to the DNA binding domain of (Drosophila trithorax) protein, and wherein said peptide is encoded by a gene located at chromosome 11 of the human genome at q23. Also provided are methods for the treatment of subject(s) suffering from immunodeficiency, developmental abnormality, inherited disease, or cancer by administering to said subject a therapeutically effective amount of one of the above-described agents (i.e., peptide, antagonist therefor, DNA encoding said peptide or antisense DNA derived therefrom). Also provided is a method for the diagnosis, in a subject, of immunodeficiency, developmental abnormality, inherited disease, or cancer associated with disruption of chromosome 11 at q23.

Description: Characterization of a Chromosome 11023 Translocation Breakpoint Associated with Acute Leukemias ACKNOWLEDGEMENT This invention was made with United States Government support under Grant No. HG00202, awarded by the National Institutes of Health and Grant No. DE-FG03- 88ER60694/A6, awarded by the Department of Energy. The United States Government may have certain rights in the invention. RELATED INVENTIONS This application is a continuation-in-part of United States Serial No. 07/954,112, filed September 30, 1992, now pending. FIELD OF THE INVENTION This invention relates to analytical and diagnostic methods, as well as novel polynucleotide sequences and peptides encoded thereby. In a particular aspect, this invention relates to methods for identifying the existence of specific chromosomal aberrations in the genome of a host subject. In another aspect, this invention relates to methods for diagnosing actual or nascent disease states employing the information obtained, applying the invention technique(s) for the determination of the presence of chromosomal aberrations. BACKGROUND OF THE INVENTION Specific chromosome translocations are characteristic of some leukaemias and solid tumors, and may lead to malignant transformation through the activation or aberrant expression of breakpoint-associated genes [Berger et al.. Leukemia Res. Vol. .6:17-26 (1982)]. For example, rearrangements involving human chromosome region llq23 are observed in acute leukaemias, especially t(4;ll), t(l;ll), and t(ll;19) in acute lymphoid leukaemias (ALL) [see, for example, Mazo et al., Proc. Natl. Acad. Sci. USA Vol. 82:2112-2116 (1990)]; and t(l;ll) t(2;ll), t(6;ll), t(9;ll), t(10;ll), t(ll;17) and t(X;ll) in acute myeloid leukaemia (AML) [see, for example, Sait et al.. Cancer Genet. Cytogenet. Vol. 2.4:181-183 (1987), Feder et al.. Cancer Genet. Cytogenet. Vol. .15:143-150), Derre et al.. Gene Chromosom. Cancer Vol. 2_\341-344 (1990, Hagemeijer et al.. Cancer Genet. Cytogenet. Vol. 5>:95-105 (1982), and Pui et al.. Blood Vol. .69:1289-1293 (1987)]. The frequency of llq23 abnormalities is particularly high in leukaemia occurring in infants, accounting for more than 75% of acute leukaemias in those under 12 months of age [see, for example, Abe et al.. Cancer Genet. Cytogenet. Vol. .9:139-144 (1983), Chuu et al.. Am. J. He atol. Vol. 3_4.:246-251 (1990), and Gibbons et al., Br. J. Hematol. Vol. .74:264-269 (1990)]. Leukaemia cells isolated from ALLs with the t(4;ll) translocation typically exhibit monocytic as well as lymphocytic characteristics, leading to speculation that the gene or genes located at the translocation breakpoint might affect development of an early lymphoid/myeloid precursor stem cell [see Rowley et al., Proc. Natl. Acad. Sci. USA Vol. £7:9358-9362 (1990)]. Previous studies have localized the t(4;ll) breakpoint and the t(9;ll) breakpoint associated with acute monoblastic (M4-AML) or myelomonocytic (M5-AMML) leukaemias to the same 5.8 kb region of chromosome llq23 [see Cimino et al.. Cancer Research Vol. .51:6712-6714 (1991)]. Recently, other studies have identified large 11 to 12 kb transcripts arising from the region of the t(4;ll) (q21:q23) translocation [see, for example, Ziemin-van der poel et al., Proc. Natl. Acad. Sci. USA Vol. 88:10735-10739 (1991), and Ci ino et al.. Cancer Research Vol. 52:3811- 3813 (1992)]. Accordingly, since consistent chromosome translocations have been associated with a number of human malignancies (including leukaemias, lymphomas and solid tumors) , and such translocations may be intimately involved in the molecular pathogenesis of the associated disorders, the development of rapid and effective methods to analyze for the presence of chromosomal aberrations related to such disease states (e.g., translocations involving a chromosomal site of interest) would provide a useful aid in the diagnosis of actual or nascent disease states. BRIEF DESCRIPTION OF THE INVENTION In order to isolate the loci of chromosome 11 involved in acute lymphoid leukaemias (ALL) and acute myeloid leukaemias (AML) , as well as other leukaemia- associated breakpoints believed to be present on chromosome 11, extensive physical mapping of chromosome llq23 was carried out by the isolation of yeast artificial chromosomes. In the course of construction of a physical map of human chromosome region llq23, the region containing the t(4;ll) and t(9;ll) translocation breakpoint was cloned, and genes whose expression is affected by chromosome rearrangement were identified. Presented herein is a physical map and the DNA sequence of the translocation breakpoint, as well as the identity of the sequences in the immediate proximity of this breakpoint. The DNA sequence of the breakpoint region shows that one of the transcripts of the DNA isolated in accordance with the present invention is interrupted as a result of translocation, and corresponds to a human gene homologous to the Drosophila trithorax (trx) gene product. BRIEF DESCRIPTION OF THE FIGURES Figure 1 shows a physical map of chromosome llq23 in the region of the t(4;ll) and t(9;ll) leukaemia- associated breakpoints. Figure 1A shows YAC clone B22B2L. The locations of transcripts from this clone are indicated in the figure, as are restriction sites (B=BssHII; E=EagrI; Nr=WruI; M= 2uI; S=SacII; N=WotI; C=C2aI; and F=Stil) . The location of the t(4;ll) and t(9;ll) breakpoints (as determined by pulsed field gel analysis) , as well as the location of the CD3 Y and δ genes, are also indicated. The centromeric end of the YAC clone lies within the CD3 gene cluster (between the CD3 δ and e genes; see Evans et al., Immunogenetics Vol. 2^:365-373 (1988)). Figure IB shows cosmid clones cl08 and cll6, and a detailed restriction map thereof (R=EcoRl; X= aI; . .EσoRl fragments subcloned into plasmid vector Bluescript for use as probes and for DNA sequence analysis result in subclones p3.8, p5, p4.3 and p4. The region of clones cl08 and cll6 subjected to DNA sequence analysis is indicated in the Figure. The complete DNA sequence of fragment p4.3 was determined using nested deletions derived from cosmid subclones p4, p5 and p4.3 as sequence templates. Figure 2 characterizes the DNA sequence where the t(4;ll) translocation breakpoint occurs, plus surrounding sequence. Figure 2A is a diagram of the structure of this region showing locations of repetitive sequences as well as putative exons of a gene spanning the breakpoint. ■ indicates the location of Alu repetitive elements; D indicates the location of sequence homologous to a portion of the LINE-1 repetitive element; indicates open reading frames representing putative exons (R = EσoRl, X = XJbal) . The location of the t(4;ll) breakpoint (as determined by Southern gel analysis on DNA from the RS4;11 cell line) is indicated in the figure. A substantial portion (~3 kb) of cDNA encoding the human trithorax gene (htrx) has been deposited in Genbank as accession number L01986. The 5' portion of this sequence is reproduced below as SEQ ID NO: 2, and the 3' portion of this sequence is reproduced below as SEQ ID NO:3. Additional sequence linking SEQ ID NO:2 and SEQ ID NO:3 is presented in SEQ ID NO:4, which also includes sequence information extending further upstream of the 5* portion set forth in SEQ ID NO:2, and further downstream of the 3' portion set forth in SEQ ID NO:3. Thus, SEQ ID NO:4 provides a substantially complete sequence of htrx-encoding cDNA. Figure 2B shows an analysis of open reading frames on either side of the breakpoint, demonstrating the occurrence of sequence similarity (and presumed homology) to the Drosophila trithorax gene product. ORFl (see SEQ ID NOs: 6 and 7) and ORF2 (see amino acid residues 1603 to 1626 of SEQ ID NO: 5) represent sequences of exons flanking the translocation breakpoint at the centromeric and telomeric sides. ORF3 (see amino acid residues 1551 to 1627 of SEQ ID NO: 5) represents the open reading frame derived from a cDNA clone corresponding to ORF2. | indicates a perfect match and + indicates a conservative substitution. Cysteine residues within the Drosophila trx zinc finger domains 2 and 6a are boxed. Figure 3 provides a genomic map of the breakpoint region on chromosome llq23. The restriction sites shown are R, EcoRI ; B, BamHI; H, Hindlll; X, Xbal . The exon/intron structure for a partial cDNA (~3kb) encoding htrxl is also shown in the figure (the 9 exons within this partial cDNA are boxed in black) . The positions of the putative zinc fingers (numbers 3-8) are indicated on a schematical representation of the protein. The position of breakpoints in cell lines has been mapped accurately while the breaks in patients are clustered over 13kb of genomic DNA shown by the shaded area on the diagram. Figure 4 provides further characterization of human trx. Thus, Figure 4(A) illustrates the pattern of cysteine (C) and histidine (H) residues in the cysteine- rich regions of htrxl . The putative zinc finger structures are indicated by lines above the sequence; the numbers above each line refer to the Drosophila zinc fingers. The dotted lines indicate alternative zinc finger domains. Figure 4(B) denotes the putative zinc finger domains of htrxl protein, including an alignment of the human trx (bottom) to the proposed finger structures of the Drosophila trx zinc fingers (top) . Drosophila domain numbers are given on the left; the last residue of each structure is given on the right. Amino acids that are identical between Drosophila and human are boxed in black; conservative changes are boxed. DETAILED DESCRIPTION OF THE INVENTION In accordance with the present invention, there are provided isolated peptide(s) having the characteristics of human trithorax protein. Invention peptides are characterized by having a DNA binding domain comprising multiple zinc fingers and at least 40% amino acid identity with respect to the DNA binding domain of Drosophila trithorax protein and at least 70% conserved sequence with respect to the DNA binding domain of Drosophila trithorax protein, wherein said peptides are encoded by a gene located at chromosome 11 of the human genome at q23. Preferred peptides of the present invention have substantially the same sequence as set forth in SEQ ID NO: 5. In accordance with another embodiment of the present invention, there are provided nucleic acids encoding peptides as described above, or nucleic acids capable of hybridizing therewith under low stringency hybridization conditions. Preferred nucleic acids according to the present invention are DNA, with particularly preferred DNA having substantially the same sequence as set forth in SEQ ID NOs: 1, 2, 3 or 4, or DNA capable of hybridizing therewith under low stringency hybridization conditions. Also contemplated by the present invention are splice variants, i.e., variant trx-encoding nucleic acids produced by differential processing of primary transcripts of geno ic DNA, resulting in the production of more than one type of mRNA. cDNA derived from differentially processed genomic DNA will encode trx proteins that have regions of complete amino acid identity and regions lacking amino acid identity (or differing by the deletion of sequences in the splice variant relative to the "parental" sequence) . Thus, the same genomic sequence can lead to the production of multiple, related mRNAs and proteins. Both the resulting mRNAs and proteins are referred to herein as "splice variants." In accordance with yet another embodiment of the present invention, there is provided antisense nucleic acid complementary to the above-described nucleic acids. As employed herein, the phrase "Drosophila trithorax gene product" refers to a trans-acting regulator of the bithorax complex in Drosophila [see, for example, Mazo et al., in Proc. Natl. Acad. Sci. USA Vol. 87:2112- 2116 (1990)]. The Drosophila trithorax gene product is an important regulatory protein which controls several derivative pathways. The Drosophila trithorax gene product is known to bind DNA at specific sites, and to regulate transcription of homeobox genes as well as the bithorax complex. The human homolog thereof, as described herein, is believed to have similarly important regulatory properties in humans. The peptide has several zinc finger domains characteristic of DNA binding proteins. The human trx protein is believed to be involved in varying stages of development, possibly by undergoing developmentally regulated alternate splicing, producing different gene products which exert different regulatory effects. As employed herein, the phrase "conservative substitution" refers to the replacement of one amino acid residue with a different amino acid residue having similar chemical and physical properties. Thus, a conservative substitution refers, for example, to the replacement of one positively charged amino acid residue with another positively charged residue. As employed herein, the phrase "isolated" refers to peptides which have been removed from their native environment, either by enrichment thereof from natural sources, by chemical synthesis, by recombinant production, and the like. Thus, the recombinant expression of human trithorax gene would produce an "isolated" peptide, since such expression would produce the peptide in a non-native environment. Similarly, substantial enrichment of the trithorax content of a cell extract would also provide an "isolated" peptide. In accordance with still another embodiment of the present invention, there is provided a method for the treatment of a subject suffering from immunodeficiency, developmental abnormality, inherited disease, or cancer, said method comprising administering to said subject a therapeutically effective amount of the above-described peptide, or antagonists thereto. In accordance with a still further embodiment of the present invention, there is provided a method for the treatment of a subject suffering from immunodeficiency states, developmental abnormalities, inherited diseases, or cancer, said method comprising administering to said subject an effective amount of the above-described antisense nucleic acid. As employed herein, the phrase "therapeutically effective amount" refers to levels of peptide, nucleic acid or pharmaceutically active compound sufficient to provide circulating concentrations high enough to effect a modulation of the biological process involved in the immunodeficiency state, developmental abnormality, inherited disease, or cancer to be treated, without substantially compromising other biological processes. Such a concentration typically falls in the range of about 10 nM up to about 1 μM, with concentrations in the range of about 100 nM up to 500 nM being presently preferred. Immunodeficiency states, developmental abnormalities, inherited diseases, or cancers contemplated for treatment in accordance with the present invention include such cancers as infantile acute lymphocytic leukemia, acute myelomonocytic leukemia, and the like. In accordance with yet another embodiment of the present invention, there is provided a method for the diagnosis, in a subject, of immunodeficiency, developmental abnormality, inherited disease, or cancer associated with alterations (e.g., deletions, disruptions, rearrangements, and the like) of chromosome 11 at q23, said method comprising analyzing biological material obtained from said subject for evidence of a defect in the gene encoding human trithorax peptide. Subjects for which the invention technique will find use include, broadly, any vertebrate species, e.g., fowl, fish, reptiles, amphibians, mammals and the like. Presently preferred subjects to be tested employing the invention technique are humans because of the ability to tailor treatment once the cause of an observed disease state is known with some certainty. The invention diagnostic technique is capable of identifying the existence of a variety of chromosomal aberrations, e.g., deletions, inversions, duplications, translocations, the formation of ringed chromosomes, and the like. In accordance with the present invention, a cell sample from a host subject is contacted with one or more probes constructed from chromosomal DNA derived from a subject of the same species as the subject being tested. The amount of detail provided by a given hybridization reaction is a function of how many probes are used for the hybridization reaction, and how much is known about each probe employed. For example, a single probe could be used, if such probe were diagnostic for a specific aberration of interest, e.g., translocation between chromosome 11 and chromosome 1, 2, 4, 6, 9, 10, 17, 22 or X. Such a probe would be derived from that portion of chromosome 11 and/or chromosome 1, 2, 4, 6, 9, 10, 17, 22 or X, where the loss and/or gain of chromosomal DNA occurs upon translocation. Thus, upon hybridization, a different pattern of hybridization between probe and test DNA will be observed, relative to the pattern of hybridization obtained with normal DNA. Alternatively, a cell sample from a subject suspected of containing a chromosomal aberration can be contacted with a panel of probes, wherein a typical "panel of probes" contains a sufficient number of probes so that, on average, for each chromosome, there are about 300 kilobases between probes. Panels can be a collection of probes which recognize total DNA from intact chromosome(s) free of aberrations, and which are derived from one or more different chromosomes. The hybridization pattern of test sample can then be compared with the hybridization pattern of said panel with normal chromosomal DNA to determine if there are any differences. A different hybridization pattern indicates the existence of one or more aberrations in the test chromosomal DNA. So long as sufficient information is available about the members of the panel of probes employed, the nature of the specific aberration observed can be determined by correlating the specific di ferences observed between the control and test hybridization patterns with the particular probe(s) which hybridizes differently in each sample. Probes employed in the practice of the present invention can be prepared employing a variety of vehicles, such as, for example, cosmids, yeast artificial chromosomes [see, for example, Burke et al., in Science 236: 806-812 (1987)], Fl plasmids [see, for example, O'Connor, et al., in Science 244: 1307-1312 (1989)], PI bacteriophage [see, for example, Sternberg in Proc. Natl. Acad. Sci. U.S.A. 87: 103-107 (1990)], and the like. Construction of cosmid libraries, for example, has been described by Evans, et al., in Gene 79: 9-20 (1989). For example, cosmid vector sCos-1 has been prepared by digesting pWE15 DNA [described by Evans and Wahl in Methods Enzymol. 152: 604-610 (1987)] with Clal + Sail and purifying the resulting 6 kb Clal-Sall fragment which lacks the cos sequence. Cosmid pDVcosl34 was digested with Clal + Xhol, and a fragment containing the duplicated cos region was purified on an LPM agarose gel. The purified fragments were ligated using T4 DNA ligase and transformed into host strain DH5. Genomic libraries can be constructed in cosmid vector(s) such as, for example, sCos-1, which contains duplicated cos sites for high efficiency microcloning, T3 and T7 bacteriophage promoters flanking the unique BamHI cloning site, two Notl sites for the excision of genomic inserts, a selectable gene (SV2-neo r ) for mammalian gene transfer, and a ColEl origin of replication. Detailed restriction maps of the cosmid insert in this vector may be rapidly determined by an end-labeling mapping procedure using T3- or T7-specific oligonucleotides. The genomic cosmid library used in this study consisted of 1.5 x 10 independent clones and was constructed by using genomic DNA digested to an average size of 100-120 kilobases with Mbol , dephosphorylated with calf intestinal phosphatase, ligated with sCos-1 DNA, and packaged with Gigapak Gold (Stratagene) in vitro packaging lysate. Only nonamplified libraries were used, and cosmid clones were archived in 96-well microtiter plates stored at -70"C in LB media with 15% (vol/vol) glycerol and kanamycin sulfate at 25 μg/ml. Specific probes which are useful in the practice of the present invention include cosmids cl08, cll6, and c4; plasmid p4.3, and the like (see Fig. 1). As an alternative to hybridization analysis, PCR probes can be derived from the unique sequences of the human trithorax gene and can be used for amplification of trithorax- encoding sequences. Exemplary PCR probes include any sequence of at least 15 contiguous nucleotides selected from Sequence ID Nos. 1, 2 3 or 4. Preferred primers comprise at least 20 contiguous nucleotides. Exemplary primer pairs include one sense primer and one anti-sense primer derived from: nucleotides 191 - 215 (or complement thereof) , inclusive, and nucleotides 760 - 786 (or complement thereof) , inclusive, as set forth in Sequence ID Nos. 1 or 2; or nucleotides 4129 - 4152 (or complement thereof) , inclusive, and nucleotides 4697 - 4723 (or complement thereof) , inclusive, as set forth in Sequence ID No. 4; nucleotides 390 - 412 (or complement thereof) , inclusive, and nucleotides 812 - 837 (or complement thereof) , inclusive, as set forth in Sequence ID Nos. 1 or 2; or nucleotides 4327 - 4349 (or complement thereof) , inclusive, and nucleotides 4749 - 4774 (or complement thereof) , inclusive, as set forth in Sequence ID No. 4; nucleotides 501 - 519 (or complement thereof) , inclusive, as set forth in Sequence ID Nos. l or 2, and nucleotides 1424-1450 of Sequence ID No. 1 (or complement thereof) , inclusive; or nucleotides 203 - 229 (or complement thereof) , inclusive, as set forth in Sequence ID No. 3; or nucleotides 4438 - 4456 (or complement thereof) , inclusive, and nucleotides 5981 - 6006 (or complement thereof) , inclusive, as set forth in Sequence ID No. 4; and the like. A variety of techniques can be employed in the practice of the present invention, for example PCR, Southern blot, chromosomal in situ suppression hybridization (as recently described in Science 247:64-69 (1990), referred to hereinafter as "CISSH") , and the like can be employed. Similar techniques which can also be employed in the practice of the present invention have been described by Lawrence et al., in Cell _______: 51-61 (1988); Pinkel at al., in Proc. Natl. Acad. Sci. U.S.A. .83.: 2934- 2938 (1986); Pinkel et al., in Proc. Natl. Acad. Sci. U.S.A. j55: 9138-9142 (1988); and Trash et al., in Genomics 5: 710-717 (1989) . Cell samples to be analyzed by CISSH can be employed directly without any particular preparation, or they can be subjected to conditions which promote growth, then arrested at metaphase [as described, for example, by Yunis and Chandler in Clinical Diagnosis and Management by Laboratory Methods. J. G. Henry, ed. (Saunders, Philadelphia) 16th Ed., pp 801-856 (1979)]. CISSH is carried out as follows. 20 to 50 ng of labeled probe DNA is combined with 1.5 to 3 μq of human placental DNA and sufficient salmon sperm DNA to obtain a total of 10 μl of hybridization cocktail. After denaturation of the probe mixture (75 " C for 5 min), preannealing of repetitive DNA sequences is allowed for 5 to 15 min (37 β C) before application to separately denatured chromosome specimens. Alternatively, in cases where no suppression and therefore no competitor DNA is needed, probe mixtures are denatured and then cooled on ice. When cosmid signals are obtained in parallel with a specific decoration (i.e., a specific label) of chromosome 11, 300 ng of pooled, labeled inserts from a chromosome 11 library is combined with the differentially labeled cosmid DNA probe. For delineation of human chromosome 11, the total DNA inserts of the library LA11NS02 derived from sorted chromosome 11 [M.A. VanDilla, et al.. Biotechnology 4:537 (1986)] were prepared as described by Lichter, et al., Human Genetics 80:224 (1988). To obtain Alu banding simultaneously with the probe signal, the competitor DNA is substituted by 300 ng of differentially labeled pBS-Alu4, and preannealing is reduced to a few seconds. Alternatively, 100 ng of labeled pBS-Alu4 is denatured in hybridization cocktail, cooled on ice, and combined with a preannealed probe just before application to slides. After overnight incubation and posthybridization washes [see Lichter, et al., supra] the specimens are incubated with blocking solution [3% bovine serum albumin (BSA) , 4 x SSC (saline sodium citrate) or, when BSA cross-reacting DNP antibodies (anti-DNP) are used, 5% nonfat dry milk, 4 x SSC] for 30 to 60 min at 37°C. For detection, all protein reagents are made up in 1% BSA, 4 x SSC, and 0.1% Tween 20 (BSA cross-reacting antibodies are preincubated in this solution for 30 min. at 37°C) and then incubated with the specimen (37°C, 30 min) and followed by washes (4 x SSC, and 0.1% Tween 20, three times for 3 min. at 42°C). Biotin-labeled probes detected by incubation with fluorescein isothiocyanate (FITC)- conjugated avidin (DCS grade; 5 /g/ml; available from Vector Laboratories, Burlingame, CA) or Texas Red isothiocyanate (TRITC)-conjugated ExtrAvidin (5 //g/ml) (Sigma) . The signal of some short DNA probes (for example, pT24-Hras) is amplified as described by D. Pinkel et al., in Proc. Natl. Acad. Sci. U.S.A. 82:2934 (1986). DNP- labeled probes are detected by incubation with rabbit-anti- DNP (7 //g/ml) (Sigma) and a second incubation with FITC- or rhodamine-conjugated goat-anti-rabbit antibodies (8 //g/ml) (Boehringer Mannheim) . Digoxigenin-labeled probes are incubated first with sheep-anti-digoxigenin Fab fragments (2.5 //g/ml) (Boehringer Mannhein) and then with FITC- conjugated donkey-anti-sheep antibodies (7 //g/ml) (Sigma) . For single probe hybridizations, labeled DNA is detected by FITC-conjugates, and chromosomal DNA is counterstained by propidium iodide (PI) (200 ng/ml PI in 2 x SSC, 5 min at room temperature) . For hybridizations with multiple differentially labeled probes, chromosomal DNA is counterstained [see Lichter et al., supra] or banded [D. Schweizer, Hum. Genet. 57: 1 (1981)] with diamidinophenylindole (DAPI) . After mounting in antifading solution [see Lichter et al; supra] the slides are evaluated on a Nikon Optiphot microscope equipped for conventional epifluorescence microscopy. For fine mapping, a modified version of the Bio-Rad laser scanning confocal microscope (Lasersharp MRC 500) is used in the photon counting mode (integration period of 0.1 to 0.3 ms per pixel) to produce digital images. The 488-nm line from an argon ion laser is used for excitation. In dual label experiments narrow band pass filters are used to obtain separate images of each fluorochrome (550-nm filter for FITC; 610-nm filter for PI or rhodamine) . In some cases, the 532-nm line from an Amoco Microlaser [frequency-doubled diode-pumped Nd:YAG (yttrium-aluminum-garnet) ] is used to excite rhodamine. The two separate images of one object are stored and then overlayed electronically. For image optimization, digital filtering is applied. Photographs can be taken from the video screen. Evidence of a defect in the gene encoding human trithorax peptide is readily obtained in a variety of ways, e.g., by detecting the occurrence of a translocation which results in disruption of said gene. This can be detected, for example, by PCR amplification of a portion of the gene encoding human trithorax peptide using PCR primers derived from unique sites located both centromeric and telomeric of the translocation breakpoint. Exemplary primers useful for this purpose include polynucleotides having at least 15 contiguous nucleotides derived from Sequence ID Nos. 1, 2, 3 or 4, as described above. Alternatively, evidence of a defect in the gene encoding human trithorax peptide can be obtained by hybridization of DNA derived from wild-type human trithorax gene region to a Southern blot of DNA obtained from the subject. As yet another alternative, evidence of a defect in the gene encoding human trithorax peptide can be obtained by in situ hybridization of DNA encoding wild-type human trithorax peptide to DNA obtained from the subject. As a still further alternative, where translocation produces a hybrid protein (characterized by containing a portion of the amino acid sequence of the human trithorax protein, and a portion of a second protein derived from the locus with which chromosome 11 cooperates in undergoing translocation) , evidence of a defect in the gene encoding human trithorax peptide can be obtained by evidence of the production of such a hybrid protein. Such hybrid proteins can be detected in a variety of ways, such as, for example, by immunoblot analysis. Similarly, evidence of a defect in the gene encoding human trithorax peptide can be obtained by evidence of the production of a hybrid nucleic acid encoding such protein. Such hybrid nucleic acids can be detected in a variety of ways, e.g., by PCR. The invention will now be described in greater detail by reference to the following non-limiting examples. Examples The following general procedures and resulting compositions are used throughout the Examples. Yeast artificial chromosome and cosmid cloning Yeast artificial chromosome human genomic libraries were generously supplied by M. Olson (St. Louis; see Browstein et al., in Science 244:1348-1351 (1989)) and D. Cohen (CEPH, Paris; see Albertsen et al., in Proc. Natl. Acad. Sci. 2:4256-4260 (1990)) and screened by PCR amplification of DNA pools [Green and Olson, Proc. Natl. Acad. Sci. USA Vol. 82:1213-1217 (1990)]. YAC clones were characterized by pulsed field electrophoresis and hybridization analysis, and in the case of clone B22B2, which contained two different YAC clones within the same yeast, were subsequently purified to a single colony by recloning, yielding B22B2L and B22B2S. Cosmids were isolated by hybridization of gel purified YAC DNA to high density chromosome-specific cosmid libraries using phenol emulsion reassociation (PERT) hybridization [Djabali et al.. Nucleic Acids Res. Vol. 2_0:6789 (1990)], or by subcloning the yeast containing YAC DNA into cosmid vector sCos-1 (Stratagene) . Yeast DNA was analyzed by restriction mapping and subcloning into cosmids. Thus, yeast DNA was partially digested with the enzyme Sau3A resulting in fragments of 10-50 kb. Fragments were size-fractionated by centrifugation through a 5-25% sucrose gradient for 17 hours, 22,000 rpm. Fractions containing fragments between 30-45 kb were pooled and 1 μg was ligated to 2 μg of BamHI digested sCos 1 vector. Cosmid DNA was packaged using the Gigapack Gold packaging extract (Stratagene) . The total library of 15,000 clones was screened with total human DNA. One hundred twenty-five clones containing human inserts were digested by .EcoRI, run on a 0.7% agarose gel, transferred on to GeneScreen membranes and used for cosmid walking experiments. Contigs were constructed by comparing restriction enzyme digestion patterns using enzymes EcoRI, BamHI and Wotl and by hybridization of the cosmids to RNA probes derived from the end of each cosmid with the T7 and T3 RNA polymerase (Stratagene) . Fluorescence in situ suppression hybridization (FISSH) In situ hybridization was carried out using normal human fibroblasts (CRL1634; Human Genetic Mutant Cell Repository, Camden NJ) or the cell line RS4;11 [see Kearney et al., "Chromosome llq23 translocations in both infant and adult acute leukaemias are detected by in situ hybridization with a yeast artificial chromosome", in Blood, in press (1992)], carrying the t(4;11) translocation as described by Selleri et al., in Proc. Natl. Acad. Sci. USA Vol. .88:887-891 (1990)]. DNA sequence analysis DNA sequence analysis was carried out by subcloning restriction fragments into plasmid vector Bluescript (Stratagene) and nested templates were created using ExoIII/Mung-bean nuclease (Stratagene) . Sequencing was carried out using an ABI 373A automated DNA sequencer. Sequences were assembled using Staden DNA sequence analysis programs running on a SUN Sparcstation. Protein sequences were compared with the Genbank databases using the BLAST program [see Stephen in J. Mol Biol. 215:403-410 (1990)]. cDNA library screening A KpnI-_EcoRI fragment derived from p4 was used as a probe to screen a human cortex cDNA library (Stratagene; see Example 3) . 10 pfu (plaque forming units) were plated and screened by standard techniques [Benton and Davis, Science Vol. 196:180-182 (1977)], and a single positive clone was identified. Using the Exassist/solr system (Stratagene) this clone was excised into plasmid Bluescript (pBS; Stratagene) . EXAMPLE 1 Molecular map of the llq23 breakpoint region To isolate translocation breakpoints of chromosome llq, a physical landmark map was constructed for human chromosome 11, using chromosome 11-specific cosmids prepared from somatic cell hybrids or flow sorted human chromosomes [see Evans and Lewis, Proc. Natl. Acad. Sci. USA Vol. .86:5030-5034 (1989)], and high resolution fluorescence in situ hybridization [see Lichter et al., Science Vol. 85:9664-9668 (1990)]. The t(4;ll) breakpoint was found to be located in the interval separating the CD3 and Thy-1 genes on chromosome llq23 [see, for example, Rowley et al. supra. Chen et al., Blood Vol. 78:2498-2504 (1991) ] . Sequence tagged sites (STSs) corresponding to the cosmid landmarks were established and used to isolate yeast artificial chromosomes from a human genomic YAC library [see, for example, Browstein et al., Science Vol. 244:1348- 1351 (1989)]. A YAC designated B22B2L was isolated as described by Rowley et al. supra. and shown to contain a portion of the CD3 gene complex extending telomeric from the CD3 e gene. Since this YAC clone was found to be inherently unstable, an additional YAC clone (CEPH 141G12) containing the breakpoint region was isolated from the CEPH YAC library [Albertsen et al., Proc. Natl. Acad. Sci. USA Vol. £2:4256-4260 (1990)] and used as a control for the integrity of YAC B22B2L. DNA probes prepared from landmark cosmids were used to locate the chromosome translocation breakpoint telomeric to the CD3 gene (see Figures 1 and 2) . By using fluorescence in situ hybridization, cosmid clones cl08 and cll6 were identified as containing the RS4;11 translocation breakpoint (see Figure IB). In addition, a detailed restriction map was determined by oligo-end labeling using T3 and T7 promoters present in the cosmid vector flanking the insert [Evans and Lewis, supra] . Moreover, the location of the t(4;ll) and t(9;ll) breakpoints in a number of patients and the RS4;11 cell line were determined by Southern blot analysis (R=EcoRI; X=XJaI; B=BamHI) . EcoRI fragments were subcloned into the plasmid vector Bluescript for use as probes and for DNA sequence analysis, resulting in subclones p3.8, p5, p4.3 and p4. The region subjected to DNA sequence analysis is indicated in the figure. Using fluorescence in situ hybridization, YAC clone B22B2L has previously been shown to contain the chromosome translocation breakpoint and to hybridize to both derivative chromosomes in the RS4;11 cell line carrying the t(4;ll) translocation, and in leukaemic cells from ALL and AML patients [Rowley et al., supra] with the t(4;ll), t(9;ll), t(6;ll) and t(ll;19) translocations. In order to further characterize this region of chromosome llq23 and to identify transcripts whose expression might be affected by these chromosome rearrangements, a cosmid contig was constructed by subcloning the B22B2L YAC DNA directly into vector sCos-1 [see Evans and Wahl, supra] r or by PERT hybridization [Djabali et al., supra1 of purified YAC DNA to high density arrays of chromosome 11-specific cosmids [see Evans et al., supra] . A physical contig map spanning more than 360 kb was constructed (see Figure 1). The t(4;ll) rearrangement was detected by pulsed field gel electrophoresis and by Southern blot analysis. Southern blot analysis was employed to localize the t(4;ll) breakpoint to a region contained within cosmid cl08 and cll6 (Figure 1) using DNA isolated from the RS4;11 and human placenta DNA digested with Pstl and XJbal. The probe was an Xbal-Kpnl f agment of subclone p4 (Figure 1) . Size markers employed were Hindlll fragments of bacteriophage lambda. The breakpoint was localized to the region covered by cosmids cl08 and cll6, about 115 kb telomeric to the CD3 y chain gene (see Figure 1). Because of the repetitive nature of probes isolated from this region, fluorescence in situ suppression hybridization (FISSH) was carried out using cosmid clones c62, cl08 and c4 (see Figure 1) to precisely define the location of the RS4;11 breakpoint as being within the cosmid contig on RS4;11 chromosomes. Cosmid clone c62 shows hybridization signals on the normal chromosome 11 and on the derivative chromosome 11, and is, therefore, localized centromeric to the llq23 breakpoint. Cosmid clone c4 shows hybridization signals on the normal chromosome 11 and on the derivative chromosome 4, and is, therefore, localized telomeric to the llq23 breakpoint. Cosmid clone cl08 shows hybridization signals on normal chromosome 11 and on both derivative chromosomes 4 and 11. Similarly, hybridization signals were detected on both derivative chromosomes 4 and 11 with cosmids cl08 and cll6, using chromosomes prepared from cell line RS4;11. The resulting map reveals the presence of four potential HTF (i.e., "Hpall-tiny fragment") islands suggested by location of clusters of CpG-rich restriction sites (see the cluster of B, E and S restriction sites (wherein B=BssHII; E=EagrI; and S=Sacll) ; the cluster of M, S, B, N, S, and N restriction sites (wherein M=MIuI and N=WotI; the cluster of N, B and B restriction sites and the cluster of E, B, C and F restriction sites in Figure 1; wherein C=C2aI and F=Stil)). The CpG cluster located nearest to the breakpoint, defined by a Notl and BssHII site contained within cosmid c62, was subsequently shown to be hypomethylated in the genome and to represent an authentic HTF island. In order to detect and define genes located near this breakpoint, unique copy probes were prepared from cosmids containing and flanking the breakpoint as follows. Human DNA inserts from the cosmids referred to above were subcloned into a plasmid vactor such as Bluescript, screened with human repetitive sequences (C 0 t-1 DNA) , and selected for sequences which did not hybridize with the repetitive sequences. These probes were used for the detection of evolutionarily conserved sequences and for detection of mRNA transcripts. Unique copy probes from cosmid cl08 (subclone p3.8) and cl3 (subclone p500) detect cross- hybridizing sequences among primates, cow and pig, indicating the presence of evolutionarily conserved and potentially coding sequences located on either side of the breakpoint. Potential genes located in the vicinity of the t(4;ll) breakpoint were detected using hybridization of unique copy DNA fragments derived from the cosmids shown in Figure 1, with "zoo" blots containing genomic DNA from various species. For example, a fragment from cosmid cl3 (p500) detected cross-hybridization with cow, pig, rabbit and rodent DNAs. A unique copy probe derived from cosmid cl08 subclone p3.8 detected cross-hybridization with primate, pig and rodent genomic DNA. EXAMPLE 2 Detection of mRNA transcripts Whole cosmid DNA or unique copy DNA probes derived from cosmid subclones detected two mRNA transcripts in the region immediately flanking the translocation breakpoint. A transcript of approximately 11.5 kb was detected in heart, lung and brain, as well as T and B lymphocytes, using cosmid cl08. Transcribed sequences were detected on Northern blot using unique copy probe derived from cosmids shown in Figure 1. A unique copy probe derived from cosmid 108 (fragment Xi»a-_EcoRl of p4) detects an 11.5 kb transcript in RNA derived from human heart, lung and brain. An additional transcript of 4.4 kb was detected in several tissues, and most intensely in placenta, pancreas, liver and kidney, using unique copy probes derived from cosmid c67. This analysis establishes the location of two transcribed sequences located in the immediate vicinity of the t(4;ll) breakpoint. The 11.5 kb transcript was also detected using cosmid cl08, spanning the breakpoint, as a probe and with unique copy subclones of cosmid cl08 located on each side of the breakpoint. EXAMPLE 3 DNA sequence of the translocation breakpoint A portion of cosmid cl08 spanning the t(4;ll) breakpoint was subcloned into the plasmid vector Bluescript and the DNA sequence determined. The DNA sequence of 6 kb containing the translocation breakpoint (see Figure 2A) was found to consist of more than 80% repetitive DNA sequences, including 9 Alu-repetitive elements [see, for example, Deininger et al., in J. Biol. Chem. 151:17-31 (1981)] and an element homologous to a segment of the LINE-1 repetitive element [see, for example, Shafit-Zagardo, et al., in Nucleic Acids Research .10.:3175-3193 (1982)]. Unique sequences of 110, 120 and 180 bp, which did not define obvious open reading frames, separated the groups of repeats. Southern blot analysis using non-repetitive probes localized the t(4;ll) breakpoint of the RS4;11 cell line to within a 1.2 kb XJaI-_EcoRI fragment consisting almost entirely of AZu sequences. The DNA sequence also revealed two regions of unique sequence with potential open reading frames located approximately 3 kb centromeric to the breakpoint and 4 kb telometric to the breakpoint. The protein sequence defined by these open reading frames was compared against known protein sequences using the computer program BLAST [see Stephen, in J. Mol. Biol. Vol. 215:403-410 (1990)]. A region of 150 bp located immediately centromeric to the .EcoRI site of clone p5 (Figure 2B) showed an extended open reading frame with highly significant similarity with the protein product of the trithorax gene of Drosophila [Mazo et al., supra] , with a Poisson probability of 0.0017 (Figure 2B) . The second open reading frame, located telometric to the breakpoint, revealed additional sequence similarity with the trithorax protein with a Poisson probability of 0.0012 (Figure 2B) . Amino-acid sequence comparison revealed that the homologies were located within the zinc finger motifs 2 and 6a of the trithorax gene (Figure 2B) . To confirm that the open reading frames corresponded to authentic mRNA transcripts, Northern blot analysis using PCR products derived from each of these sequences was carried out. Probes from each open reading frame independently detected the 11.5 kb mRNA transcript, suggesting that these sequences represent exons of a large trithorax-like gene spanning the breakpoint. In order to further characterize this transcript, a genomic fragment corresponding to ORF2 (Fragment _Kp.nl- .EcoRI of p4) was used to isolate cDNA clones from a human brain cDNA library. A partial cDNA clone of 3 kb was isolated and the DNA sequence of the portion corresponding to ORF2 determined. This sequence revealed an open reading frame with highly significant sequence similarity to the Drosophila trithorax gene product (Figure 2B) and demonstrates complete conservation of all of the cysteine residues which form a zinc finger-like structure. Thus, it is concluded that the gene spanning the t(4;ll) breakpoint (denoted Htrxl) encodes a protein with a high degree of sequence homology to the Drosophila trithorax gene and is therefore likely to encode a mammalian transcriptional regulatory factor. The complete sequence of this 3kb partial cDNA clone has been determined and is presented as residues 3944 - 6982 in Sequence ID No. 4. This sequence information has been deposited with Genbank (Accession No. L01986) . EXAMPLE 4 Analysis of t(4;ll) and t(9;ll) breakpoints in patients To determine the consistency of the breakpoint in different patients with t(4;ll) ALL and t(9;ll) AML rearrangements, DNA from adult leukaemic patients and from cell line RS4;11 were evaluated by Southern blotting using unique copy probes (prepared as described in Example 1) which flank the RS4;11 breakpoint. Patient DNA was digested with BamHI, .EcoRI, and XJbal, and subjected to Southern blot analysis, using single copy probes isolated from cosmid cl08. The 1 kb XJbaI-_EcoRI probe isolated from the 3.8 kb .EcoRI fragment reveals an 18 kb non-rearranged BatπHI fragment in the RS4;11 cell line as well as in leukaemic cells from t(4;ll) and t(9;ll) patients. The X£>aI-.EcoRI probe isolated from clone p4 reveals a 15 kb non-rearranged BamHI fragment. These results indicate that in the RS4;11 cell line, in t(4;ll) leukaemic cells, and in t(9;ll) leukaemic cells, all of the breakpoints are contained within the same 9 kb BatπHl fragment of cosmid 108. DNA derived from 8 infant leukaemia patients was digested with .EcoRI and evaluated by Southern blot hybridization using the 1 kb XJaI-_EcoRI probe. This analysis revealed rearrangements in one t(9;ll) leukaemic patient and three t(4;ll) leukaemia patients, and suggests that, in this small series, all of the breakpoints are located within the same 5 kb region. The .EcoRI (p4) fragment is not rearranged in the RS4;11 cell line and therefore the breakpoint can be further localized in this cell line to within a 1.2 kb XJbaI-_EcoRI fragment consisting entirely of Alu elements. Due to the repetitive nature of this sequence, the precise location of the breakpoint cannot readily be determined. EXAMPLE 5 Genomic structure of Htrxl around the breakpoints The intron-exon structure of the partial cDNA spanning the breakpoints was established using the different EcoRI fragments of the cDNA as probes on cosmid 116 digested by EcoRI, BamHl and BamHl/EcoRl. This approach determined the minimum number of introns contained within the 3 kb cDNA. In order to define exactly the position and length of each of these introns direct sequencing of the cosmid was performed using oligonucleotides defined on the cDNA sequence. These results are summarized in Figure 3. EXAMPLE 6 Patient studies Clustering of the breakpoints on chromosome llq23 has been demonstrated in infant leukaemic patients with t(4;ll) and t(9;ll) translocations using genomic probes derived from cosmids spanning the region [see Mazo et al., in Proc. Natl. Acad. Sci. USA 82:2112-2116 (1990); Cimino et al., in Cancer Research .51:6712-6714 (1991); Ziemin-van der Poel et al. , in Proc. Natl. Acad. Sci. USA 88:10735- 10739 (1991); and Cimino et al., in Cancer Research 52.:3811-3813 (1992)]. The 3kb cDNA used as a probe on Southern blots of adult leukaemia cell DNA detects rearrangements in patients with t(4;ll) [6 of 7 patients studied], t(6;ll) [2 of 2 patients studied], t(9;ll) [1 of 1 patient studied] and t(10;ll) [1 of 1 patient studied] with the enzyme EcoRI (Fig. 3; Table). The single patient (number 7) with t(4;ll) in whom the rearrangement was not demonstrated showed the rearrangement with a more centromeric probe. The breakpoints in the two cell lines RS4;11 and Karpas 45 containing t(4;ll) and t(X;ll) respectively have been mapped more precisely using a number of restriction enzymes and EcoRI fragments of the cDNA. In these cell lines the breakpoints lie in two different introns and are separated by approximately 5 kb (see Fig. 3). TABLE 1 Patient Age Sex Leukaemia Karyotype 46, XX, t(4;ll)(q21;q23). 1* 46, XX, t(4;ll) (q21;q23) . 2 46, XY, t(4;ll) (q21;q23) . 3 46, XX, t(4;ll)(q21;q23). 4 46, XX, t(4;ll) (q21;q23), add (7) (pi?), 5 add (9)(pl?), add(17) (pi?), -19 51, XX, +X, +1, +4, t(4;ll)(q21;q23), 6* +8, der(18), (17;?) (qlO;?) , +21. 52, XY, +X, +add(3)(q?), t(4;ll) (q21;q23) , I N V +6, +13, +15, inc. I 8* 46, XY, t(6;ll) (q27;q23) . 9* 46, XY, dir ins (6;11) (q27;ql3q23) 10* 59 tAML-Ml 46, XX, t(9;ll) (p22;q23). 11* 27 M AML-M5 46, XY, t(10;ll) (pl2;q23). RS4:11S <1 ALL-L2 46, XX, t(4;ll)(q21;q23), i(7)(ql0) 91, Y, -X, -X, -Y, t(l;5)(q25;ql3). Karpas 455 M T-All der(ll)t(X;ll) (ql3;q23), t[der(ll)t(X;ll)(ql3;q23);14)[pl5;qll], Described in *Kearney et al., Blood 80:1659-1665 (1992), SStrong et al., Blood 65:21-31 (1985), HKarpas et al., Leukemia Research .1:35-49 (1976) EXAMPLE 7 Htrx Expression The expression of Htrxl in cell lines of lymphoid origin was assessed by Northern analysis. Total RNA from T and B lymphocyte lines representing various differentiated states were separated, transferred onto membrane and Htrx-specific sequences detected using the 3kb cDNA as a probe. Three transcripts of 15, 12.5 and 11.5kb were detected in the mature T cell lines, Jurkat and HUT78, as well as the immature T cell line CEM. Likewise, all three transcripts were expressed in the IgM-secreting B cell line Namalwa. In contrast only the largest transcript was present at detectable levels in the murine pre-B-like cell line 70/3. 70/3 cells can be induced to progress towards a more mature B cell phenotype by treatment with bacterial lipopolysaccharide (LPS) (Paige, et al., Nature, 292:631-633 (1980)). Six hours of treatment with a final concentration of 10//g/ml LPS upregulates the level of the 15kb Htrxl transcript and stimulates the expression of the 12.5kb mRNA. In addition, the expression of Htrxl was analyzed in normal human adult tissues, transcripts were detected in brain, pancreas, liver, lung, heart, kidney, skeletal muscle, but were absent in placenta. While the invention has been described in detail with reference to certain preferred embodiments thereof, it will be understood that modifications and variations are within the spirit and scope of that which is described and claimed. Summary of Sequences Sequence ID No. 1 is a substantial portion of the DNA sequence for the human trithorax gene (htrx) . Sequence ID No. 2 is the 5 1 portion of the -3 kb cDNA encoding the human trithorax gene (htrx) . The sequence of the -3 kb partial clone of htrx has been deposited in Genbank as accession number L01986. Sequence ID No. 3 is the 3' portion of the -3 kb cDNA encoding htrx. Sequence ID No. 4 is the nucleotide sequence of a cDNA encoding the human trithorax (htrx) , and the deduced amino acid sequence thereof. Sequence ID No. 5 is the deduced amino acid sequence of human trithorax (htrx) . Sequence ID No. 6 is a genomic nucleotide sequence encoding ORFl (see Fig. 2B) , and the deduced amino acid sequence thereof. Sequence ID No. 7 is a portion of the human trithorax peptide upstream of the llq23 translocation breakpoint (see ORFl in Fig. 2B) . Sequence ID No. 8 is a portion of the Drosophila trithorax peptide corresponding to ORFl (see SEQ ID NO:7) . Sequence ID No. 9 is the deduced amino acid sequence of a portion of the human trithorax peptide downstream of the llq23 translocation breakpoint (see ORF2 in Fig. 2B) . Sequence ID No. 10 is a portion of the Drosophila trithorax peptide corresponding to ORF2 (see SEQ ID NO:9). Sequence ID No. 11 is the deduced amino acid sequence derived from a cDNA derived from the genomic nucleic acid sequence which encodes the amino acid sequence set forth in Sequence ID No. 5 (see ORF3 in Fig. 2B) . Sequence ID No. 12 is a portion of the Drosophila trithorax peptide corresponding to ORF3 (see SEQ ID NO: 11). SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Evans, Glen A. Djabali, Malek Selleri, Licia Parry, Pauline (ii) TITLE OF INVENTION: CHARACTERIZATION OF A CHROMOSOME 11Q23 TRANSLOCATION BREAKPOINT ASSOCIATED WITH ACUTE LEUKEMIAS (iii) NUMBER OF SEQUENCES: 12 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Pretty, Schroeder, Brueggemann & Clark (B) STREET: 444 South Flower Street, Suite 2000 (C) CITY: Los Angeles (D) STATE: California (E) COUNTRY: USA (F) ZIP: 90071 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: US 08/061,376 (B) FILING DATE: 13-MAY-1993 (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Reiter, Stephen E. (B) REGISTRATION NUMBER: 31,192 (C) REFERENCE/DOCKET NUMBER: P41 9387 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (619)546-4737 (B) TELEFAX: (619)546-9392 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2429 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: GAATTCCGAA AGAAGTTCCC AAAACCACTC CTAGTGAGCC CAAGAAAAAG CAGCCTCCAC 60 CACCAGAATC AGGTCCAGAG CAGAGCAAAC AGAAAAAAGT GGCTCCCCGC CCAAGTATCC 120 CTGTAAAACA AAAACCAAAA GAAAAGGAAA AACCACCTCC GGTCAATAAG CAGGAGAATG 180 CAGGCACTTT GAACATCCTC AGCACTCTCT CCAATGGCAA TAGTTCTAAG CAAAAAATTC 240 CAGCAGATGG AGTCCACAGG ATCAGAGTGG ACTTTAAGGA GGATTGTGAA GCAGAAAATG 300 TGTGGGAGAT GGGAGGCTTA GGAATCTTGA CTTCTGTTCC TATAACACCC AGGGTGGTTT 360 GCTTTCTCTG TGCCAGTAGT GGGCATGTAG AGTTTGTGTA TTGCCAAGTC TGTTGTGAGC 420 CCTTCCACAA GTTTTGTTTA GAGGAGAACG AGCGCCCTCT GGAGGACCAG CTGGAAAATT 480 GGTGTTGTCG TCGTTGCAAA TTCTGTCACG TTTGTGGAAG GCAACATCAG GCTACAAAGC 540 AGCTGCTGGA GTGTAATAAG TGCCGAAACA GCTATCACCC TGAGTGCCTG GGACCAAACT 600 ACCCCACCAA ACCCACAAAG AAGAAGAAAG TCTGGATCTG TACCAAGTGT GTTCGCTGTA 660 AGAGCTGTGG ATCCACAACN CCAGGCAAAG GGTGGGATGC ACAGTGGTCT CATGATTTCT 720 CACTGTNTCA TGATTGCGCC AAGCTCTTTG CTAAAGGAAA CTTCTGCCCT CTCTGTGACA 780 AATGTTATGA TGATGATGAC TATGAGAGTA AGATGATGCA ATGTGGAAAG TGTGATCGCT 840 GGGTCCATTC CAAATGTGAG AATCTTTCAG ATGAGATGTA TGAGATTCTA TCTAATCTGC 900 CAGAAAGTGT GGCCTACACT TGTGTGAACT GTACTGAGCG GCACCCTGCA GAGTGGCGAC 960 TGGCCCTTGA AAAAGAGCTG CAGATTTCTC TGAAGCAAGT TCTGACAGCT TTTGTTGAAT 1020 TCTCGGACTA CCCAGCCATT TGCTACGGTA CCGGCAAGCC TGCCAAGCTC CAGACTTAAA 1080 TCCCGAAGAC AAGAGGAGAG ATACCTTNCC GAAGTTCCCC CGAAGGCCCT GATCCACCAG 1140 TNTTACTTAA GGCAACAAAC ANGGGTGCCA ACAGCCTTAG NCCTNGAAGG GCAAGAGGAG 1200 GTTGCCCAGG NTGNGCAGCT TTNANCAGGG NAACAGCTNA NNTGNAATCT NCNAAAACCA 1260 GGACCACCGT GGTTNCTGNC NCACACCTGN ACCAGCAACT ANCACCTNCA TGTGTCCCCG 1320 AGCCAAGAAC TGTGNCTTCT GGATGATAAA AAAAGTATAT TGCCAACGAC ATCGGGATTT 1380 GATCAAAGGC GAAAGTGGTC CNANAATGGA TTTGAAGTTT TCAGAAGAAG TGTTTGTGGA 1440 CTTTGAAGGA ATCAGCTTGA GAAGGGAAGT TTCTCAATGG CTTGGAACCA GAAAATATCC 1500 ACATGATGAT TGGGNCTATG ACAATCGACT GCTTAGGAAT TCTAAATGAT CTCTCCGACT 1560 GTGAAGATAA GCTCTTTCCT ATTGGATATC AGTGTCCCAG GGTATACTGG AGCACCACAG 1620 ATGCTCGCAA GCGCTGTGTA TATACATGCA AGATAGTGGA GTGCCGTCCT CCAGTCGTAG 1680 AGCCGGATAT CAACAGCACT GTTGAACATG ATGAAAACAG GACCATTGCC CATAGTCCAA 1740 CATCTTTTAC AGAAAGTTCA TCAAAAGAGA GTCAAAACAC AGCTGAAATT ATAAGTCCTC 1800 CATCACCAGA CCGACCTCCT CATTCACAAA CCTCTGGCTC CTGTTATTAT CATGTCATCT 1860 CAAAGGTCCC CAGGATTCGA ACACCCAGTT ATTCTCCAAC ACAGAGATCC CCTGGCTGTC 1920 GACCGTTGCC TTCTGCAGGA AGTCCTACCC CAACCACTCA TGAAATAGTC ACAGTGAGGT 1980 GATTCTTTAC TCTCCTCTGG ACTTCGAAGC ATTGGCNCCA GGCGTCACAG TACCTCTTCC 2040 TTATCACCCC AGCGGTCCAA ACTCCGGATA ATGTCTCCAA TGAGAACTGG GAATACTTAC 2100 TCTAGGAATA ATGTTTCCTC AGTCTCCACC ACCGGGACCG CTACTGATCT TGAATCAAGT 2160 GCCAAAGTAG TTGATCATGT CTTAGGGCCA CTGAATTCAA GTACTAGTTT AGGGCAAAAC 2220 ACTTCCACCT CTTCAAATTT GCAAAGGACA GTGGTTACTG TAGGCAATAA AAACAGTTCA 2280 CTTGGATGGA TCTTCATCTT CAGAAATGAA GCAGTCCAGT GCTTCAGACT TGGTGTCCAA 2340 GAGCTCCTCT TTAAAGGGAG AGAAGACCAA AGTGCTGAGT TCCAAGAGCT CAGAGGGATC 2400 TGCACATAAT GTGGCTTACC CTGGAATTC 2429 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1147 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: GAATTCCGAA AGAAGTTCCC AAAACCACTC CTAGTGAGCC CAAGAAAAAG CAGCCTCCAC 60 CACCAGAATC AGGTCCAGAG CAGAGCAAAC AGAAAAAAGT GGCTCCCCGC CCAAGTATCC 120 CTGTAAAACA AAAACCAAAA GAAAAGGAAA AACCACCTCC GGTCAATAAG CAGGAGAATG 180 CAGGCACTTT GAACATCCTC AGCACTCTCT CCAATGGCAA TAGTTCTAAG CAAAAAATTC 240 CAGCAGATGG AGTCCACAGG ATCAGAGTGG ACTTTAAGGA GGATTGTGAA GCAGAAAATG 300 TGTGGGAGAT GGGAGGCTTA GGAATCTTGA CTTCTGTTCC TATAACACCC AGGGTGGTTT 360 GCTTTCTCTG TGCCAGTAGT GGGCATGTAG AGTTTGTGTA TTGCCAAGTC TGTTGTGAGC 420 CCTTCCACAA GTTTTGTTTA GAGGAGAACG AGCGCCCTCT GGAGGACCAG CTGGAAAATT 480 GGTGTTGTCG TCGTTGCAAA TTCTGTCACG TTTGTGGAAG GCAACATCAG GCTACAAAGC 540 AGCTGCTGGA GTGTAATAAG TGCCGAAACA GCTATCACCC TGAGTGCCTG GGACCAAACT 600 ACCCCACCAA ACCCACAAAG AAGAAGAAAG TCTGGATCTG TACCAAGTGT GTTCGCTGTA 660 AGAGCTGTGG ATCCACAACN CCAGGCAAAG GGTGGGATGC ACAGTGGTCT CATGATTTCT 720 CACTGTNTCA TGATTGCGCC AAGCTCTTTG CTAAAGGAAA CTTCTGCCCT CTCTGTGACA 780 AATGTTATGA TGATGATGAC TATGAGAGTA AGATGATGCA ATGTGGAAAG TGTGATCGCT 840 GGGTCCATTC CAAATGTGAG AATCTTTCAG ATGAGATGTA TGAGATTCTA TCTAATCTGC 900 CAGAAAGTGT GGCCTACACT TGTGTGAACT GTACTGAGCG GCACCCTGCA GAGTGGCGAC 960 TGGCCCTTGA AAAAGAGCTG CAGATTTCTC TGAAGCAAGT TCTGACAGCT TTTGTTGAAT 1020 TCTCGGACTA CCCAGCCATT TGCTACGGTA CCGGCAAGCC TGCCAAGCTC CAGACTTAAA 1080 TCCCGAAGAC AAGAGGAGAG ATACCTTNCC GAAGTTCCCC CGAAGGCCCT GATCCACCAG 1140 TNTTACT 1147 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1208 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: TNANCAGGGN AACAGCTNAN NTGNAATCTN CNAAAACCAG GACCACCGTG GTTNCTGNCN 60 CACACCTGNA CCAGCAACTA NCACCTNCAT GTGTCCCCGA GCCAAGAACT GTGNCTTCTG 120 GATGATAAAA AAAGTATATT GCCAACGACA TCGGGATTTG ATCAAAGGCG AAAGTGGTCC 180 NANAATGGAT TTGAAGTTTT CAGAAGAAGT GTTTGTGGAC TTTGAAGGAA TCAGCTTGAG 240 AAGGGAAGTT TCTCAATGGC TTGGAACCAG AAAATATCCA CATGATGATT GGGNCTATGA 300 CAATCGACTG CTTAGGAATT CTAAATGATC TCTCCGACTG TGAAGATAAG CTCTTTCCTA 360 TTGGATATCA GTGTCCCAGG GTATACTGGA GCACCACAGA TGCTCGCAAG CGCTGTGTAT 420 ATACATGCAA GATAGTGGAG TGCCGTCCTC CAGTCGTAGA GCCGGATATC AACAGCACTG 480 TTGAACATGA TGAAAACAGG ACCATTGCCC ATAGTCCAAC ATCTTTTACA GAAAGTTCAT 540 CAAAAGAGAG TCAAAACACA GCTGAAATTA TAAGTCCTCC ATCACCAGAC CGACCTCCTC 600 ATTCACAAAC CTCTGGCTCC TGTTATTATC ATGTCATCTC AAAGGTCCCC AGGATTCGAA 660 CACCCAGTTA TTCTCCAACA CAGAGATCCC CTGGCTGTCG ACCGTTGCCT TCTGCAGGAA 720 GTCCTACCCC AACCACTCAT GAAATAGTCA CAGTGAGGTG ATTCTTTACT CTCCTCTGGA 780 CTTCGAAGCA TTGGCNCCAG GCGTCACAGT ACCTCTTCCT TATCACCCCA GCGGTCCAAA 840 CTCCGGATAA TGTCTCCAAT GAGAACTGGG AATACTTACT CTAGGAATAA TGTTTCCTCA 900 GTCTCCACCA CCGGGACCGC TACTGATCTT GAATCAAGTG CCAAAGTAGT TGATCATGTC 960 TTAGGGCCAC TGAATTCAAG TACTAGTTTA GGGCAAAACA CTTCCACCTC TTCAAATTTG 1020 CAAAGGACAG TGGTTACTGT AGGCAATAAA AACAGTTCAC TTGGATGGAT CTTCATCTTC 1080 AGAAATGAAG CAGTCCAGTG CTTCAGACTT GGTGTCCAAG AGCTCCTCTT TAAAGGGAGA 1140 GAAGACCAAA GTGCTGAGTT CCAAGAGCTC AGAGGGATCT GCACATAATG TGGCTTACCC 1200 TGGAATTC 1208 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11907 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: ATGGCGCACA GCTGTCGGTG GCGCTTCCCC GCCCGACCCG GGACCACCGG GGGCGGCGGC 60 GGCGGGGGGC GCCGGGGCCT AGGGGGCGAC CCGCGGCAAC GCGTCCCGGC CCTGCTGCTT 120 CCCCCCGGGC CCCCGGTCGG CGGTGGCGGC CCCGGGGCGC CCCCCTCCCC CCCGGCTGTG 180 GCGGCCGCGG CGGCGGCGGC GGGAAGCAGC GGGGCTGGGG TTCCAGGGGG AGCGGCCGCC 240 GCCTCAGCAG CCTCCTCGTC GTCCGCCTCG TCTTCGTCTT CGTCATCGTC CTCAGCCTCT 300 TCAGGGCCGG CCCTGCTCCG GGTGGGCCCG GGCTTCGACG CGGCGCTGCA GGTCTCGGCC 360 GCCATCGGCA CCAACCTGCG CCGGTTCCGG GCCGTGTTTG GGGAGAGCGG CGGGGGAGGC 420 GGCAGCGGAG AGGATGAGCA ATTCTTAGGT TTTGGCTCAG ATGAAGAAGT CAGAGTGCGA 480 AGTCCCACAA GGTCTCCTTC AGTTAAAACT AGTCCTCGAA AACCTCGTGG GAGACCTAGA 540 AGTGGCTCTG ACCGAAATTC AGCTATCCTC TCAGATCCAT CTGTGTTTTC CCCTCTAAAT 600 AAATCAGAGA CCAAATCTGG AGATAAGATC AAGAAGAAAG ATTCTAAAAG TATAGAAAAG 660 AAGAGAGGAA GACCTCCCAC CTTCCCTGGA GTAAAAATCA AAATAACACA TGGAAAGGAC 720 ATTTCAGAGT TACCAAAGGG AAACAAAGAA GATAGCCTGA AAAAAATTAA AAGGACACCT 780 TCTGCTACGT TTCAGCAAGC CACAAAGATT AAAAAATTAA GAGCAGGTAA ACTCTCTCCT 840 TCAAGTCTAA GTTTAAGACA GGGAAGCTTC AAATAGGAAG GAAGGGGGTA CAAATTGTAG 900 ACGGAGAGGA AGGCCTCCAT CAACAGAAAG GATAAAGACC CCTTCGGTCT CCTCATTATT 960 CTGAACTGGA AAAGCCCCAG AAAGTCCGGA AAGACAAGGA AGGAACACCT CCACTTACAA 1020 AAGAAGATAA GACAGTTGTC AGACAAAGCC CTCGAAGGAT TAAGCCAGTT AGGATTATTC 1080 CTTCTTCAAA AAGGACAGAT GCAACCATTG CTAAGCAACT CTTACAGAGG GCAAAAAAAG 1140 GGGGCTCAAA AGAAAATTGA AAAAGAAGCA GCTCAGCTGC AGGGAAGAAA GGTGAAGACA 1200 CAGGTCAAAA ATATTCGACA GTTCATCATG CCTGTTGTCA GTGCTATCTC CTCGCGGATC 1260 ATTAAGACCC CTCGGCGGTT TATAGAGGAT GAGGATTATG ACCCTCCAAT TAAAATTGCC 1320 CGATTAGAGT CTACACCGAA TAGTAGATTC AGTGCCCCGT CCTGTGGATC TTCTGAAAAA 1380 TCAAGTGCAG CTTCTCAGCA CTCCTCTCAA ATGTCTTCAG ACTCCTCTCG ATCTAGTAGC 1440 CCCAGTGTTG ATACCTCCAC AGACTCTCAG GCTTCTGAGG AGATTCAGGT ACTTCCTGAG 1500 GAGCGGAGCG ATACCCCTGA AGTTCATCCT CCACTGCCCA TTTCCCAGTC CCCAGAAAAT 1560 GAGAGTAATG ATAGGAGAAG CAGAAGGTAT TCAGTGTCGG AGAGAAGTTT TGGATCTAGA 1620 ACGACGAAAA AATTATCAAC TCTACAAAGT GCCCCCCAGC AGCAGACCTC CTCGTCTCCA 1680 CCTCCACCTC TGCTGACTCC ACCGCCACCA CTGCAGCCAG CCTCCAGTAT CTCTGACCAC 1740 ACACCTTGGC TTATGCCTCC AACAATCCCC TTAGCATCAC CATTTTTGCC TGCTTCCACT 1800 GCTCCTATGC AAGGGAAGCG AAAATCTATT TTGCGAGAAC CGACATTTAG GTGGACTTCT 1860 TTAAAGCATT CTAGGTCAGA GCCACAATAC TTTTCCTCAG CAAAGTATGC CAAAGAAGGT 1920 CTTATTCGCA AACCAATATT TGATAATTTC CGACCCCCTC CACTAACTCC CGAGGACGTT 1980 GGCTTTGCAT CTGGTTTTTC TGCATCTGGT ACCGCTGCTT CAGCCCGATT GTTTTCGCCA 2040 CTCCATTCTG GAACAAGGTT TGATATGCAC AAAAGGAGCC CTCTTCTGAG AGCTCCAAGA 2100 TTTACTCCAA GTGAGGCTCA CTCTAGAATA TTTGAGTCTG TAACCTTGCC TAGTAATCGA 2160 ACTTCTGCTG GAACATCTTC TTCAGGAGTA TCCAATAGAA AAAGGAAAAG AAAAGTGTTT 2220 AGTCCTATTC GATCTGAACC AAGATCTCCT TCTCACTCCA TGAGGACAAG AAGTGGAAGG 2280 CTTAGTAGTT CTGAGCTCTC ACCTCTCACC CCCCCGTCTT CTGTCTCTTC CTCGTTAAGC 2340 ATTTCTGTTA GTCCTCTTGC CACTAGTGCC TTAAACCCAA CTTTTACTTT TCCTTCTCAT 2400 TCCCTGACTC AGTCTGGGGA ATCTGCAGAG AAAAATCAGA GACCAAGGAA GCAGACTAGT 2460 GCTCCGGCAG AGCCATTTTC ATCAAGTAGT CCTACTCCTC TCTTCCCTTG GTTTACCCCA 2520 GGCTCTCAGA CTGAAAGAGG GAGAAATAAA GACAAGGCCC CCGAGGAGCT GTCCAAAGAT 2580 CGAGATGCTG ACAAGAGCGT GGAGAAGGAC AAGAGTAGAG AGAGAGACCG GGAGAGAGAA 2640 AAGGAGAATA AGCGGGAGTC AAGGAAAGAG AAAAGGAAAA AGGGATCAGA AATTCAGAGT 2700 AGTTCTGCTT TGTATCCTGT GGGTAGGGTT TCCAAAGAGA AGGTTGTTGG TGAAGATGTT 2760 GCCACTTCAT CTTCTGCCAA AAAAGCAACA GGGCGGAAGA AGTCTTCATC ACATGATTCT 2820 GGGACTGATA TTACTTCTGT GACTCTTGGG GATACAACAG CTGTCAAAAC CAAAATACTT 2880 ATAAAGAAAG GGAGAGGAAA TCTGGAAAAA ACCAACTTGG ACCTCGGCCC AACTGCCCCA 2940 TCCCTGGAGA AGGAGAAAAC CCTCTGCCTT TCCACTCCTT CATCTAGCAC TGTTAAACAT 3000 TCCACTTCCT CCATAGGCTC CATGTTGGCT CAGGCAGACA AGCTTCCAAT GACTGACAAG 3060 AGGGTTGCCA GCCTCCTAAA AAAGGCCAAA GCTCAGCTCT GCAAGATTGA GAAGAGTAAG 3120 AGTCTTAAAC AAACCGACCA GCCCAAAGCA CAGGGTCAAG AAAGTGACTC ATCAGAGACC 3180 TCTGTGCGAG GACCCCGGAT TAAACATGTC TGCAGAAGAG CAGCTGTTGC CCTTGGCCGA 3240 AAACGAGCTG TGTTTCCTGA TGACATGCCC ACCCTGAGTG CCTTACCATG GGAAGAACGA 3300 GAAAAGATTT TGTCTTCCAT GGGGAATGAT GACAAGTCAT CAATTGCTGG CTCAGAAGAT 3360 GCTGAACCTC TTGCTCCACC CATCAAACCA ATTAAACCTG TCACTAGAAA CAAGGCACCC 3420 CAGGAACCTC CAGTAAAGAA AGGACGTCGA TCGAGGCGGT GTGGGCAGTG TCCCGGCTGC 3480 CAGGTGCCTG AGGACTGTGG TGTTTGTACT AATTGCTTAG ATAAGCCCAA GTTTGGTGGT 3540 CGCAATATAA AGAAGCAGTG CTGCAAGATG AGAAAATGTC AGAATCTACA ATGGATGCCT 3600 TCCAAAGCCT ACCTGCAGAA GCAAGCTAAA GCTGTGAAAA AGAAAGAGAA AAAGTCTAAG 3660 ACCAGTGAAA AGAAAGACAG CAAAGAGAGC AGTGTTGTGA AGAACGTGGT GGACTCTAGT 3720 CAGAAACCTA CCCCATCAGC AAGAGAGGAT CCTGCCCCAA AGAAAAGCAG TAGTGAGCCT 3780 CCTCCACGAA AGCCCGTCGA GGAAAAGAGT GAAGAAGGGA ATGTCTCGGC CCCTGGGCCT 3840 GAATCCAAAC AGGCCACCAC TCCAGCTTCC AGGAAGTCAA GCAAGCAGGT CTCCCAGCCA 3900 GCACTGGTCA TCCCGCCTCA GCCACCTACT ACAGGACCGC CAAGAAAAGA AGTTCCCAAA 3960 ACCACTCCTA GTGAGCCCAA GAAAAAGCAG CCTCCACCAC CAGAATCAGG TCCAGAGCAG 4020 AGCAAACAGA AAAAAGTGGC TCCCCGCCCA AGTATCCCTG TAAAACAAAA ACCAAAAGAA 4080 AAGGAAAAAC CACCTCCGGT CAATAAGCAG GAGAATGCAG GCACTTTGAA CATCCTCAGC 4140 ACTCTCTCCA ATGGCAATAG TTCTAAGCAA AAAATTCCAG CAGATGGAGT CCACAGGATC 4200 AGAGTGGACT TTAAGGAGGA TTGTGAAGCA GAAAATGTGT GGGAGATGGG AGGCTTAGGA 4260 ATCTTGACTT CTGTTCCTAT AACACCCAGG GTGGTTTGCT TTCTCTGTGC CAGTAGTGGG 4320 CATGTAGAGT TTGTGTATTG CCAAGTCTGT TGTGAGCCCT TCCACAAGTT TTGTTTAGAG 4380 GAGAACGAGC GCCCTCTGGA GGACCAGCTG GAAAATTGGT GTTGTCGTCG TTGCAAATTC 4440 TGTCACGTTT GTGGAAGGCA ACATCAGGCT ACAAAGCAGC TGCTGGAGTG TAATAAGTGC 4500 CGAAACAGCT ATCACCCTGA GTGCCTGGGA CCAAACTACC CCACCAAACC CACAAAGAAG 4560 AAGAAAGTCT GGATCTGTAC CAAGTGTGTT CGCTGTAAGA GCTGTGGATC CACAACTCCA 4620 GGCAAAGGGT GGGATGCACA GTGGTCTCAT GATTTCTCAC TGTGTCATGA TTGCGCCAAG 4680 CTCTTTGCTA AAGGAAACTT CTGCCCTCTC TGTGACAAAT GTTATGATGA TGATGACTAT 4740 GAGAGTAAGA TGATGCAATG TGGAAAGTGT GATCGCTGGG TCCATTCCAA ATGTGAGAAT 4800 CTTTCAGATG AGATGTATGA GATTCTATCT AATCTGCCAG AAAGTGTGGC CTACACTTGT 4860 GTGAACTGTA CTGAGCGGCA CCCTGCAGAG TGGCGACTGG CCCTTGAAAA AGAGCTGCAG 4920 ATTTCTCTGA AGCAAGTTCT GACAGCTTTG TTGAATTCTC GGACTACCAG CCATTTGCTA 4980 CGCTACCGGC AGGCTGCCAA GCCTCCAGAC TTAAATCCCG AGACAGAGGA GAGTATACCT 5040 TCCCGCAGCT CCCCCGAAGG ACCTGATCCA CCAGTTCTTA CTGAGGTCAG CAAACAGGAT 5100 GATCAGCAGC CTTTAGATCT AGAAGGAGTC AAGAGGAAGA TGGACCAAGG GAATTACACA 5160 TCTGTGTTGG AGTTCAGTGA TGATATTGTG AAGATCATTC AAGCAGCCAT TAATTCAGAT 5220 GGAGGACAGC CAGAAATTAA AAAAGCCAAC AGCATGGTCA AGTCCTTCTT CATTCGGCAA 5280 ATGGAACGTG TTTTTCCATG GTTCAGTGTC AAAAAGTCCA GGTTTTGGGA GCCAAATAAA 5340 GTATCAAGCA ACAGTGGGAT GTTACCAAAC GCAGTGCTTC CACCTTCACT TGACCATAAT 5400 TATGCTCAGT GGCAGGAGCG AGAGGAAAAC AGCCACACTG AGCAGCCTCC TTTAATGAAG 5460 AAAATCATTC CAGCTCCCAA ACCCAAAGGT CCTGGAGAAC CAGACTCACC AACTCCTCTG 5520 CATCCTCCTA CACCACCAAT TTTGAGTACT GATAGGAGTC GAGAAGACAG TCCAGAGCTG 5580 AACCCACCCC CAGGCATAGA AGACAATAGA CAGTGTGCGT TATGTTTGAC TTATGGTGAT 5640 GACAGTGCTA ATGATGCTGG TCGTTTACTA TATATTGGCC AAAATGAGTG GACACATGTA 5700 AATTGTGCTT TGTGGTCAGC GGAAGTGTTT GAAGATGATG ACGGATCACT AAAGAATGTG 5760 CATATGGCTG TGATCAGGGG CAAGCAGCTG AGATGTGAAT TCTGCCAAAA GCCAGGAGCC 5820 ACCGTGGGTT GCTGTCTCAC ATCCTGCACC AGCAACTATC ACTTCATGTG TTCCCGAGCC 5880 AAGAACTGTG TCTTTCTGGA TGATAAAAAA GTATATTGCC AACGACATCG GGATTTGATC 5940 AAAGGCGAAG TGGTTCCTGA GAATGGATTT GAAGTTTTCA GAAGAGTGTT TGTGGACTTT 6000 GAAGGAATCA GCTTGAGAAG GAAGTTTCTC AATGGCTTGG AACCAGAAAA TATCCACATG 6060 ATGATTGGGT CTATGACAAT CGACTGCTTA GGAATTCTAA ATGATCTCTC CGACTGTGAA 6120 GATAAGCTCT TTCCTATTGG ATATCAGTGT TCCAGGGTAT ACTGGAGCAC CACAGATGCT 6180 CGCAAGCGCT GTGTATATAC ATGCAAGATA GTGGAGTGCC GTCCTCCAGT CGTAGAGCCG 6240 GATATCAACA GCACTGTTGA ACATGATGAA AACAGGACCA TTGCCCATAG TCCAACATCT 6300 TTTACAGAAA GTTCATCAAA AGAGAGTCAA AACACAGCTG AAATTATAAG TCCTCCATCA 6360 CCAGACCGAC CTCCTCATTC ACAAACCTCT GGCTCCTGTT ATTATCATGT CATCTCAAAG 6420 GTCCCCAGGA TTCGAACACC CAGTTATTCT CCAACACAGA GATCCCCTGG CTGTCGACCG 6480 TTGCCTTCTG CAGGAAGTCC TACCCCAACC ACTCATGAAA TAGTCACAGT AGGTGATCCT 6540 TTACTCTCCT CTGGACTTCG AAGCATTGGC TCCAGGCGTC ACAGTACCTC TTCCTTATCA 6600 CCCCAGCGGT CCAAACTCCG GATAATGTCT CCAATGAGAA CTGGGAATAC TTACTCTAGG 6660 AATAATGTTT CCTCAGTCTC CACCACCGGG ACCGCTACTG ATCTTGAATC AAGTGCCAAA 6720 GTAGTTGATC ATGTCTTAGG GCCACTGAAT TCAAGTACTA GTTTAGGGCA AAACACTTCC 6780 ACCTCTTCAA ATTTGCAAAG GACAGTGGTT ACTGTAGGCA ATAAAAACAG TCACTTGGAT 6840 GGATCTTCAT CTTCAGAAAT GAAGCAGTCC AGTGCTTCAG ACTTGGTGTC CAAGAGCTCC 6900 TCTTTAAAGG GAGAGAAGAC CAAAGTGCTG AGTTCCAAGA GCTCAGAGGG ATCTGCACAT 6960 AATGTGGCTT ACCCTGGAAT TCCTAAACTG GCCCCACAGG TTCATAACAC AACATCTAGA 7020 GAACTGAATG TTAGTAAAAT CGGCTCCTTT GCTGAACCCT CTTCAGTGTC GTTTTCTTCT 7080 AAAGAGGCCC TCTCCTTCCC ACACCTCCAT TTGAGAGGGC AAAGGAATGA TCGAGACCAA 7140 CACACAGATT CTACCCAATC AGCAAACTCC TCTCCAGATG AAGATACTGA AGTCAAAACC 7200 TTGAAGCTAT CTGGAATGAG CAACAGATCA TCCATTATCA ACGAACATAT GGGATCTAGT 7260 TCCAGAGATA GGAGACAGAA AGGGAAAAAA TCCTGTAAAG AAACTTTCAA AGAAAAGCAT 7320 TCCAGTAAAT CTTTTTTGGA ACCTGGTCAG GTGACAACTG GTGAGGAAGG AAACTTGAAG 7380 CCAGAGTTTA TGGATGAGGT TTTGACTCCT GAGTATATGG GCCAACGACC ATGTAACAAT 7440 GTTTCTTCTG ATAAGATTGG TGATAAAGGC CTTTCTATGC CAGGAGTCCC CAAAGCTCCA 7500 CCCATGCAAG TAGAAGGATC TGCCAAGGAA TTACAGGCAC CACGGAAACG CACAGTCAAA 7560 GTGACACTGA CACCTCTAAA AATGGAAAAT GAGAGTCAAT CCAAAAATGC CCTGAAAGAA 7620 AGTAGTCCTG CTTCCCCTTT GCAAATAGAG TCAACATCTC CCACAGAACC AATTTCAGCC 7680 TCTGAAAATC CAGGAGATGG TCCAGTGGCC CAACCAAGCC CCAATAATAC CTCATGCCAG 7740 GATTCTCAAA GTAACAACTA TCAGAATCTT CCAGTACAGG ACAGAAACCT AATGCTTCCA 7800 GATGGCCCCA AACCTCAGGA GGATGGCTCT TTTAAAAGGA GGTATCCCCG TCGCAGTGCC 7860 CGTGCACGTT CTAACATGTT TTTTGGGCTT ACCCCACTCT ATGGAGTAAG ATCCTATGGT 7920 GAAGAAGACA TTCCATTCTA CAGCAGCTCA ACTGGGAAGA AGCGAGGCAA GAGATCAGCT 7980 GAAGGACAGG TGGATGGGGC CGATGACTTA AGCACTTCAG ATGAAGACGA CTTATACTAT 8040 TACAACTTCA CTAGAACAGT GATTTCTTCA GGTGGAGAGG AACGACTGGC ATCCCATAAT 8100 TTATTTCGGG AGGAGGAACA GTGTGATCTT CCAAAAATCT CACAGTTGGA TGGTGTTGAT 8160 GATGGGACAG AGAGTGATAC TAGTGTCACA GCCACAACAA GGAAAAGCAG CCAGATTCCA 8220 AAAAGAAATG GTAAAGAAAA TGGAACAGAG AACTTAAAGA TTGATAGACC TGAAGATGCT 8280 GGGGAGAAAG AACATGTCAC TAAGAGTTCT GTTGGCCACA AAAATGAGCC AAAGATGGAT 8340 AAAACTGGGA TTCATTCTTC CCAGCGTGAT CTTGATTCTG AACTTTACCC AGACGGTAGA CGCTCCTAAT AGCATGGGAC TCCTCAGCTG TGCAAGCCAG CCCCACCTCT CCTGGGGGTT GGACAGCGGT CAGCAAGCCC TTCAGTGCCG GGTCCCACTA CGGTTTCAGC TGCCTCTAGA CAAAGGGAAT GGCAAGAAGC ACCAGTTCTT CTGAAGCACA CATTCCAGAC CAAGAAACGA GGGACTCCAG GAGCAGAGGC TGAGCAGCAG GATACAGCTA AAGGAGTGTG GGCAACCTGC AGGGCAAGTC GCTGTTCTTC AATCCAGCAA ATGAACAAGA AAGTGCAGAA CCTAAAACAG TTCAGCTCCC CACTGATGCT TTGGCTTCAG CAAGAACAAA GAGAAAAAAC CCAAGAAAGG ACTTGTTTTT GAAATTTCCA TGTGCAGAAA GTATTGAAGA TGCCTGGAAG TCATTGACAG TCAAATGCCC GCCTAAAGCA GCTCTCATTT GCAGGTGTTA ATTCTCCATG ATGCAGTTGT GTTCCTCATT GAGCAGCTGT AATTACAAAT TCCGTTTCCA CAAGCCAGAG GAGGCCAATG GGCTCAGCCA GGGCTGAAGT CCACCTCAGG AAGTCAGCAT GCTTCTAAAC ATCGTCAGCC TCCTGAATAC AACCCCAATG CAGCTGAAGT CAGCTCGGAG GGCAACTAGC ATGGATCTGC CACTTAAAAA AGACTTCTAA GGAGGCAGTT GGTGTCTACA GGTCTTTTCT GTAAGAGAAA CATTGATGCA GGTGAGATGG GTCATCCGCT CCATCCAGAC TGACAAGCGG GAAAAGTATT TGCTATATGT TCCGAATTGA TGACTCAGAG GTAGTGGATG GCACGCTTCA TCAATCACTC GTGTGAGCCT AACTGCTATT GGGCAGAAGC ACATTGTCAT CTTTGCCATG CGTAAGATCT TACGACTATA AGTTCCCCAT TGAGGATGCC AGCAACAAGC AAGAAATGCC GGAAGTTCCT AAACTAA (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3969 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: Met Ala His Ser Cys Arg Trp Arg Phe Pro Ala Arg Pro Gly Thr Thr 1 5 10 15 Gly Gly Gly Gly Gly Gly Gly Arg Arg Gly Leu Gly Gly Asp Pro Arg 20 25 30 Gin Arg Val Pro Ala Leu Leu Leu Pro Pro Gly Pro Pro Val Gly Gly 35 40 45 Gly Gly Pro Gly Ala Pro Pro Ser Pro Pro Ala Val Ala Ala Ala Ala 50 55 60 Ala Ala Ala Gly Ser Ser Gly Ala Gly Val Pro Gly Gly Ala Ala Ala 65 70 75 80 Ala Ser Ala Ala Ser Ser Ser Ser Ala Ser Ser Ser Ser Ser Ser Ser 85 90 95 Ser Ser Ala Ser Ser Gly Pro Ala Leu Leu Arg Val Gly Pro Gly Phe 100 105 110 Asp Ala Ala Leu Gin Val Ser Ala Ala lie Gly Thr Asn Leu Arg Arg 115 120 125 Phe Arg Ala Val Phe Gly Glu Ser Gly Gly Gly Gly Gly Ser Gly Glu 130 135 140 Asp Glu Gin Phe Leu Gly Phe Gly Ser Asp Glu Glu Val Arg Val Arg 145 150 155 160 Ser Pro Thr Arg Ser Pro Ser Val Lys Thr Ser Pro Arg Lys Pro Arg 165 170 175 Gly Arg Pro Arg Ser Gly Ser Asp Arg Asn Ser Ala lie Leu Ser Asp 180 185 190 Pro Ser Val Phe Ser Pro Leu Asn Lys Ser Glu Thr Lys Ser Gly Asp 195 200 205 Lys lie Lys Lys Lys Asp Ser Lys Ser lie Glu Lys Lys Arg Gly Arg 210 215 220 Pro Pro Thr Phe Pro Gly Val Lys lie Lys lie Thr His Gly Lys Asp 225 230 235 240 lie Ser Glu Leu Pro Lys Gly Asn Lys Glu Asp Ser Leu Lys Lys lie 245 250 255 Lys Arg Thr Pro Ser Ala Thr Phe Gin Gin Ala Thr Lys lie Lys Lys 260 265 270 Leu Arg Ala Gly Lys Leu Ser Pro Ser Ser Leu Ser Leu Arg Gin Gly 275 280 285 Ser Phe Lys Glx Glu Gly Arg Gly Tyr Lys Leu Glx Thr Glu Arg Lys 290 295 300 Ala Ser lie Asn Arg Lys Asp Lys Asp Pro Phe Gly Leu Leu lie lie 305 310 315 320 Leu Asn Trp Lys Ser Pro Arg Lys Ser Gly Lys Thr Arg Lys Glu His 325 330 335 Leu His Leu Gin Lys Lys lie Arg Gin Leu Ser Asp Lys Ala Leu Glu 340 345 350 Gly Leu Ser Gin Leu Gly Leu Phe Leu Leu Gin 355 360 Pro Leu Leu Ser Asn Ser Tyr Arg Gly Gin Lys 370 375 Lys He Glu Lys Glu Ala Ala Gin Leu Gin Gly 385 390 395 Gin Val Lys Asn He Arg Gin Phe He Met Pro 405 410 Ser Ser Arg He He Lys Thr Pro Arg Arg Phe 420 425 Tyr Asp Pro Pro He Lys He Ala Arg Leu Glu 435 440 Arg Phe Ser Ala Pro Ser Cys Gly Ser Ser Glu 450 455 Ser Gin His Ser Ser Gin Met Ser Ser Asp Ser 465 470 475 Pro Ser Val Asp Thr Ser Thr Asp Ser Gin Ala 485 490 Val Leu Pro Glu Glu Arg Ser Asp Thr Pro Glu 500 505 Pro He Ser Gin Ser Pro Glu Asn Glu Ser Asn 515 520 Arg Tyr Ser Val Ser Glu Arg Ser Phe Gly Ser 530 535 Leu Ser Thr Leu Gin Ser Ala Pro Gin Gin Gin 545 550 555 Pro Pro Pro Leu Leu Thr Pro Pro Pro Pro Leu 565 570 He Ser Asp His Thr Pro Trp Leu Met Pro Pro 580 585 Ser Pro Phe Leu Pro Ala Ser Thr Ala Pro Met 595 600 Ser He Leu Arg Glu Pro Thr Phe Arg Trp Thr 610 615 Arg Ser Glu Pro Gin Tyr Phe Ser Ser Ala Lys 625 630 635 Leu He Arg Lys Pro He Phe Asp Asn Phe Arg 645 650 Pro Glu Asp Val Gly Phe Ala Ser Gly Phe Ser 660 665 Ala Ser Ala Arg Leu Phe Ser Pro Leu His Ser 675 680 Met His Lys Arg Ser Pro Leu Leu Arg Ala Pro 690 695 Glu Ala His Ser Arg He Phe Glu Ser Val Thr Leu Pro Ser Asn Arg 705 710 715 720 Thr Ser Ala Gly Thr Ser Ser Ser Gly Val Ser Asn Arg Lys Arg Lys 725 730 735 Arg Lys Val Phe Ser Pro He Arg Ser Glu Pro Arg Ser Pro Ser His 740 745 750 Ser Met Arg Thr Arg Ser Gly Arg Leu Ser Ser Ser Glu Leu Ser Pro 755 760 765 Leu Thr Pro Pro Ser Ser Val Ser Ser Ser Leu Ser He Ser Val Ser 770 775 780 Pro Leu Ala Thr Ser Ala Leu Asn Pro Thr Phe Thr Phe Pro Ser His 785 790 795 800 Ser Leu Thr Gin Ser Gly Glu Ser Ala Glu Lys Asn Gin Arg Pro Arg 805 810 815 Lys Gin Thr Ser Ala Pro Ala Glu Pro Phe Ser Ser Ser Ser Pro Thr 820 825 830 Pro Leu Phe Pro Trp Phe Thr Pro Gly Ser Gin Thr Glu Arg Gly Arg 835 840 845 Asn Lys Asp Lys Ala Pro Glu Glu Leu Ser Lys Asp Arg Asp Ala Asp 850 855 860 Lys Ser Val Glu Lys Asp Lys Ser Arg Glu Arg Asp Arg Glu Arg Glu 865 870 875 880 Lys Glu Asn Lys Arg Glu Ser Arg Lys Glu Lys Arg Lys Lys Gly Ser 885 890 895 Glu He Gin Ser Ser Ser Ala Leu Tyr Pro Val Gly Arg Val Ser Lys 900 905 910 Glu Lys Val Val Gly Glu Asp Val Ala Thr Ser Ser Ser Ala Lys Lys 915 920 925 Ala Thr Gly Arg Lys Lys Ser Ser Ser His Asp Ser Gly Thr Asp He 930 935 940 Thr Ser Val Thr Leu Gly Asp Thr Thr Ala Val Lys Thr Lys He Leu 945 950 955 960 He Lys Lys Gly Arg Gly Asn Leu Glu Lys Thr Asn Leu Asp Leu Gly 965 970 975 Pro Thr Ala Pro Ser Leu Glu Lys Glu Lys Thr Leu Cys Leu Ser Thr 980 985 990 Pro Ser Ser Ser Thr Val Lys His Ser Thr Ser Ser He Gly Ser Met 995 1000 1005 Leu Ala Gin Ala Asp Lys Leu Pro Met Thr Asp Lys Arg Val Ala Ser 1010 1015 1020 Leu Leu Lys Lys Ala Lys Ala Gin Leu Cys Lys He Glu Lys Ser Lys 1025 1030 1035 1040 Ser Leu Lys Gin Thr Asp Gin Pro Lys Ala Gin Gly Gin Glu Ser Asp 1045 1050 1055 Ser Ser Glu Thr Ser Val Arg Gly Pro Arg He Lys His Val Cys Arg 1060 1065 1070 Arg Ala Ala Val Ala Leu Gly Arg Lys Arg Ala Val Phe Pro Asp Asp 1075 1080 1085 Met Pro Thr Leu Ser Ala Leu Pro Trp Glu Glu Arg Glu Lys He Leu 1090 1095 1100 Ser Ser Met Gly Asn Asp Asp Lys Ser Ser He Ala Gly Ser Glu Asp 1105 1110 1115 1120 Ala Glu Pro Leu Ala Pro Pro He Lys Pro He Lys Pro Val Thr Arg 1125 1130 1135 Asn Lys Ala Pro Gin Glu Pro Pro Val Lys Lys Gly Arg Arg Ser Arg 1140 1145 1150 Arg Cys Gly Gin Cys Pro Gly Cys Gin Val Pro Glu Asp Cys Gly Val 1155 1160 1165 Cys Thr Asn Cys Leu Asp Lys Pro Lys Phe Gly Gly Arg Asn He Lys 1170 1175 1180 Lys Gin Cys Cys Lys Met Arg Lys Cys Gin Asn Leu Gin Trp Met Pro 1185 1190 1195 1200 Ser Lys Ala Tyr Leu Gin Lys Gin Ala Lys Ala Val Lys Lys Lys Glu 1205 1210 1215 Lys Lys Ser Lys Thr Ser Glu Lys Lys Asp Ser Lys Glu Ser Ser Val 1220 1225 1230 Val Lys Asn Val Val Asp Ser Ser Gin Lys Pro Thr Pro Ser Ala Arg 1235 1240 1245 Glu Asp Pro Ala Pro Lys Lys Ser Ser Ser Glu Pro Pro Pro Arg Lys 1250 1255 1260 Pro Val Glu Glu Lys Ser Glu Glu Gly Asn Val Ser Ala Pro Gly Pro 1265 1270 1275 1280 Glu Ser Lys Gin Ala Thr Thr Pro Ala Ser Arg Lys Ser Ser Lys Gin 1285 1290 1295 Val Ser Gin Pro Ala Leu Val He Pro Pro Gin Pro Pro Thr Thr Gly 1300 1305 1310 Pro Pro Arg Lys Glu Val Pro Lys Thr Thr Pro Ser Glu Pro Lys Lys 1315 1320 1325 Lys Gin Pro Pro Pro Pro Glu Ser Gly Pro Glu Gin Ser Lys Gin Lys 1330 1335 1340 Lys Val Ala Pro Arg Pro Ser He Pro Val Lys Gin Lys Pro Lys Glu 1345 1350 1355 1360 Lys Glu Lys Pro Pro Pro Val Asn Lys Gin Glu Asn Ala Gly Thr Leu 1365 1370 1375 Asn He Leu Ser Thr Leu Ser Asn Gly Asn Ser Ser Lys Gin Lys He 1380 1385 1390 Pro Ala Asp Gly Val His Arg He Arg Val Asp Phe Lys Glu Asp Cys 1395 1400 1405 Glu Ala Glu Asn Val Trp Glu Met Gly Gly Leu Gly He Leu Thr Ser 1410 1415 1420 Val Pro He Thr Pro Arg Val Val Cys Phe Leu Cys Ala Ser Ser Gly 1425 1430 1435 1440 His Val Glu Phe Val Tyr Cys Gin Val Cys Cys Glu Pro Phe His Lys 1445 1450 1455 Phe Cys Leu Glu Glu Asn Glu Arg Pro Leu Glu Asp Gin Leu Glu Asn 1460 1465 1470 Trp Cys Cys Arg Arg Cys Lys Phe Cys His Val Cys Gly Arg Gin His 1475 1480 1485 Gin Ala Thr Lys Gin Leu Leu Glu Cys Asn Lys Cys Arg Asn Ser Tyr 1490 1495 1500 His Pro Glu Cys Leu Gly Pro Asn Tyr Pro Thr Lys Pro Thr Lys Lys 1505 1510 1515 1520 Lys Lys Val Trp He Cys Thr Lys Cys Val Arg Cys Lys Ser Cys Gly 1525 1530 1535 Ser Thr Thr Pro Gly Lys Gly Trp Asp Ala Gin Trp Ser His Asp Phe 1540 1545 1550 Ser Leu Cys His Asp Cys Ala Lys Leu Phe Ala Lys Gly Asn Phe Cys 1555 1560 1565 Pro Leu Cys Asp Lys Cys Tyr Asp Asp Asp Asp Tyr Glu Ser Lys Met 1570 1575 1580 Met Gin Cys Gly Lys Cys Asp Arg Trp Val His Ser Lys Cys Glu Asn 1585 1590 1595 1600 Leu Ser Asp Glu Met Tyr Glu He Leu Ser Asn Leu Pro Glu Ser Val 1605 1610 1615 Ala Tyr Thr Cys Val Asn Cys Thr Glu Arg His Pro Ala Glu Trp Arg 1620 1625 1630 Leu Ala Leu Glu Lys Glu Leu Gin He Ser Leu Lys Gin Val Leu Thr 1635 1640 1645 Ala Leu Leu Asn Ser Arg Thr Thr Ser His Leu Leu Arg Tyr Arg Gin 1650 1655 1660 Ala Ala Lys Pro Pro Asp Leu Asn Pro Glu Thr Glu Glu Ser He Pro 1665 1670 1675 1680 Ser Arg Ser Ser Pro Glu Gly Pro Asp Pro Pro Val Leu Thr Glu Val 1685 1690 1695 Ser Lys Gin Asp Asp Gin Gin Pro Leu Asp Leu Glu Gly Val Lys Arg 1700 1705 1710 Lys Met Asp Gin Gly Asn Tyr Thr Ser Val Leu Glu Phe Ser Asp Asp 1715 1720 1725 He Val Lys He He Gin Ala Ala He Asn Ser Asp Gly Gly Gin Pro 1730 1735 1740 Glu He Lys Lys Ala Asn Ser Met Val Lys Ser Phe Phe He Arg Gin 1745 1750 1755 1760 Met Glu Arg Val Phe Pro Trp Phe Ser Val Lys Lys Ser Arg Phe Trp 1765 1770 1775 Glu Pro Asn Lys Val Ser Ser Asn Ser Gly Met Leu Pro Asn Ala Val 1780 1785 1790 Leu Pro Pro Ser Leu Asp His Asn Tyr Ala Gin Trp Gin Glu Arg Glu 1795 1800 1805 Glu Asn Ser His Thr Glu Gin Pro Pro Leu Met Lys Lys He He Pro 1810 1815 1820 Ala Pro Lys Pro Lys Gly Pro Gly Glu Pro Asp Ser Pro Thr Pro Leu 1825 1830 1835 1840 His Pro Pro Thr Pro Pro He Leu Ser Thr Asp Arg Ser Arg Glu Asp 1845 1850 1855 Ser Pro Glu Leu Asn Pro Pro Pro Gly He Glu Asp Asn Arg Gin Cys 1860 1865 1870 Ala Leu Cys Leu Thr Tyr Gly Asp Asp Ser Ala Asn Asp Ala Gly Arg 1875 1880 1885 Leu Leu Tyr He Gly Gin Asn Glu Trp Thr His Val Asn Cys Ala Leu 1890 1895 1900 Trp Ser Ala Glu Val Phe Glu Asp Asp Asp Gly Ser Leu Lys Asn Val 1905 1910 1915 1920 His Met Ala Val He Arg Gly Lys Gin Leu Arg Cys Glu Phe Cys Gin 1925 1930 1935 Lys Pro Gly Ala Thr Val Gly Cys Cys Leu Thr Ser Cys Thr Ser Asn 1940 1945 1950 Tyr His Phe Met Cys Ser Arg Ala Lys Asn Cys Val Phe Leu Asp Asp 1955 1960 1965 Lys Lys Val Tyr Cys Gin Arg His Arg Asp Leu He Lys Gly Glu Val 1970 1975 1980 Val Pro Glu Asn Gly Phe Glu Val Phe Arg Arg Val Phe Val Asp Phe 1985 1990 1995 2000 Glu Gly He Ser Leu Arg Arg Lys Phe Leu Asn Gly Leu Glu Pro Glu 2005 2010 2015 Asn He His Met Met He Gly Ser Met Thr He Asp Cys Leu Gly He 2020 2025 2030 Leu Asn Asp Leu Ser Asp Cys Glu Asp Lys Leu Phe Pro He Gly Tyr 2035 2040 2045 Gin Cys Ser Arg Val Tyr Trp Ser Thr Thr Asp Ala Arg Lys Arg Cys 2050 2055 2060 Val Tyr Thr Cys Lys He Val Glu Cys Arg Pro Pro Val Val Glu Pro 2065 2070 2075 2080 Asp He Asn Ser Thr Val Glu His Asp Glu Asn Arg Thr He Ala His 2085 2090 2095 Ser Pro Thr Ser Phe Thr Glu Ser Ser Ser Lys Glu Ser Gin Asn Thr 2100 2105 2110 Ala Glu He He Ser Pro Pro Ser Pro Asp Arg Pro Pro His Ser Gin 2115 2120 2125 Thr Ser Gly Ser Cys Tyr Tyr His Val He Ser Lys Val Pro Arg He 2130 2135 2140 Arg Thr Pro Ser Tyr Ser Pro Thr Gin Arg Ser Pro Gly Cys Arg Pro 2145 2150 2155 2160 Leu Pro Ser Ala Gly Ser Pro Thr Pro Thr Thr His Glu He Val Thr 2165 2170 2175 Val Gly Asp Pro Leu Leu Ser Ser Gly Leu Arg Ser He Gly Ser Arg 2180 2185 2190 Arg His Ser Thr Ser Ser Leu Ser Pro Gin Arg Ser Lys Leu Arg He 2195 2200 2205 Met Ser Pro Met Arg Thr Gly Asn Thr Tyr Ser Arg Asn Asn Val Ser 2210 2215 2220 Ser Val Ser Thr Thr Gly Thr Ala Thr Asp Leu Glu Ser Ser Ala Lys 2225 2230 2235 2240 Val Val Asp His Val Leu Gly Pro Leu Asn Ser Ser Thr Ser Leu Gly 2245 2250 2255 Gin Asn Thr Ser Thr Ser Ser Asn Leu Gin Arg Thr Val Val Thr Val 2260 2265 2270 Gly Asn Lys Asn Ser His Leu Asp Gly Ser Ser Ser Ser Glu Met Lys 2275 2280 2285 Gin Ser Ser Ala Ser Asp Leu Val Ser Lys Ser Ser Ser Leu Lys Gly 2290 2295 2300 Glu Lys Thr Lys Val Leu Ser Ser Lys Ser Ser Glu Gly Ser Ala His 2305 2310 2315 2320 Asn Val Ala Tyr Pro Gly He Pro Lys Leu Ala Pro Gin Val His Asn 2325 2330 2335 Thr Thr Ser Arg Glu Leu Asn Val Ser Lys He Gly Ser Phe Ala Glu 2340 2345 2350 Pro Ser Ser Val Ser Phe Ser Ser Lys Glu Ala Leu Ser Phe Pro His 2355 2360 2365 Leu His Leu Arg Gly Gin Arg Asn Asp Arg Asp Gin His Thr Asp Ser 2370 2375 2380 Thr Gin Ser Ala Asn Ser Ser Pro Asp Glu Asp Thr Glu Val Lys Thr 2385 2390 2395 2400 Leu Lys Leu Ser Gly Met Ser Asn Arg Ser Ser He He Asn Glu His 2405 2410 2415 Met Gly Ser Ser Ser Arg Asp Arg Arg Gin Lys Gly Lys Lys Ser Cys 2420 2425 2430 Lys Glu Thr Phe Lys Glu Lys His Ser Ser Lys Ser Phe Leu Glu Pro 2435 2440 2445 Gly Gin Val Thr Thr Gly Glu Glu Gly Asn Leu Lys Pro Glu Phe Met 2450 2455 2460 Asp Glu Val Leu Thr Pro Glu Tyr Met Gly Gin Arg Pro Cys Asn Asn 2465 2470 2475 2480 Val Ser Ser Asp Lys He Gly Asp Lys Gly Leu Ser Met Pro Gly Val 2485 2490 2495 Pro Lys Ala Pro Pro Met Gin Val Glu Gly Ser Ala Lys Glu Leu Gin 2500 2505 2510 Ala Pro Arg Lys Arg Thr Val Lys Val Thr Leu Thr Pro Leu Lys Met 2515 2520 2525 Glu Asn Glu Ser Gin Ser Lys Asn Ala Leu Lys Glu Ser Ser Pro Ala 2530 2535 2540 Ser Pro Leu Gin He Glu Ser Thr Ser Pro Thr Glu Pro He Ser Ala 2545 2550 2555 2560 Ser Glu Asn Pro Gly Asp Gly Pro Val Ala Gin Pro Ser Pro Asn Asn 2565 2570 2575 Thr Ser Cys Gin Asp Ser Gin Ser Asn Asn Tyr Gin Asn Leu Pro Val 2580 2585 2590 Gin Asp Arg Asn Leu Met Leu Pro Asp Gly Pro Lys Pro Gin Glu Asp 2595 2600 2605 Gly Ser Phe Lys Arg Arg Tyr Pro Arg Arg Ser Ala Arg Ala Arg Ser 2610 2615 2620 Asn Met Phe Phe Gly Leu Thr Pro Leu Tyr Gly Val Arg Ser Tyr Gly 2625 2630 2635 2640 Glu Glu Asp He Pro Phe Tyr Ser Ser Ser Thr Gly Lys Lys Arg Gly 2645 2650 2655 Lys Arg Ser Ala Glu Gly Gin Val Asp Gly Ala Asp Asp Leu Ser Thr 2660 2665 2670 Ser Asp Glu Asp Asp Leu Tyr Tyr Tyr Asn Phe Thr Arg Thr Val He 2675 2680 2685 Ser Ser Gly Gly Glu Glu Arg Leu Ala Ser His Asn Leu Phe Arg Glu 2690 2695 2700 Glu Glu Gin Cys Asp Leu Pro Lys He Ser Gin Leu Asp Gly Val Asp 2705 2710 2715 2720 Asp Gly Thr Glu Ser Asp Thr Ser Val Thr Ala Thr Thr Arg Lys Ser 2725 2730 2735 Ser Gin He Pro Lys Arg Asn Gly Lys Glu Asn Gly Thr Glu Asn Leu 2740 2745 2750 Lys He Asp Arg Pro Glu Asp Ala Gly Glu Lys Glu His Val Thr Lys 2755 2760 2765 Ser Ser Val Gly His Lys Asn Glu Pro Lys Met Asp Asn Cys His Ser 2770 2775 2780 Val Ser Arg Val Lys Thr Gin Gly Gin Asp Ser Leu Glu Ala Gin Leu 2785 2790 2795 2800 Ser Ser Leu Glu Ser Ser Arg Arg Val His Thr Ser Thr Pro Ser Asp 2805 2810 2815 Lys Asn Leu Leu Asp Thr Tyr Asn Thr Glu Leu Leu Lys Ser Asp Ser 2820 2825 2830 Asp Asn Asn Asn Ser Asp Asp Cys Gly Asn He Leu Pro Ser Asp He 2835 2840 2845 Met Asp Phe Val Leu Lys Asn Thr Pro Ser Met Gin Ala Leu Gly Glu 2850 2855 2860 Ser Pro Glu Ser Ser Ser Ser Glu Leu Leu Asn Leu Gly Glu Gly Leu 2865 2870 2875 2880 Gly Leu Asp Ser Asn Arg Glu Lys Asp Met Gly Leu Phe Glu Val Phe 2885 2890 2895 Ser Gin Gin Leu Pro Thr Thr Glu Pro Val Asp Ser Ser Val Ser Ser 2900 2905 2910 Ser He Ser Ala Glu Glu Gin Phe Glu Leu Pro Leu Glu Leu Pro Ser 2915 2920 2925 Asp Leu Ser Val Leu Thr Thr Arg Ser Pro Thr Val Pro Ser Gin Asn 2930 2935 2940 Pro Ser Arg Leu Ala Val He Ser Asp Ser Gly Glu Lys Arg Val Thr 2945 2950 2955 2960 He Thr Glu Lys Ser Val Ala Ser Ser Glu Ser Asp Pro Ala Leu Leu 2965 2970 2975 Ser Pro Gly Val Asp Pro Thr Pro Glu Gly His Met Thr Pro Asp His 2980 2985 2990 Phe He Gin Gly His Met Asp Ala Asp His He Ser Ser Pro Pro Cys 2995 3000 3005 Gly Ser Val Glu Gin Gly His Gly Asn Asn Gin Asp Leu Thr Arg Asn 3010 3015 3020 Ser Ser Thr Pro Gly Leu Gin Val Pro Val Ser Pro Thr Val Pro He 3025 3030 3035 3040 Gin Asn Gin Lys Tyr Val Pro Asn Ser Thr Asp Ser Pro Gly Pro Ser 3045 3050 3055 Gin He Ser Asn Ala Ala Val Gin Thr Thr Pro Pro His Leu Lys Pro 3060 3065 3070 Ala Thr Glu Lys Leu He Val Val Asn Gin Asn Met Gin Pro Leu Tyr 3075 3080 3085 Val Leu Gin Thr Leu Pro Asn Gly Val Thr Gin Lys He Gin Leu Thr 3090 3095 3100 Ser Ser Val Ser Ser Thr Pro Ser Val Met Glu Thr Asn Thr Ser Val 3105 3110 3115 3120 Leu Gly Pro Met Gly Gly Gly Leu Thr Leu Thr Thr Gly Leu Asn Pro 3125 3130 3135 Ser Leu Pro Thr Ser Gin Ser Leu Phe Pro Ser Ala Ser Lys Gly Leu 3140 3145 3150 Leu Pro Met Ser His His Gin His Leu His Ser Phe Pro Ala Ala Thr 3155 3160 3165 Gin Ser Ser Phe Pro Pro Asn He Ser Asn Pro Pro Ser Gly Leu Leu 3170 3175 3180 He Gly Val Gin Pro Pro Pro Asp Pro Gin Leu Leu Val Ser Glu Ser 3185 3190 3195 3200 Ser Gin Arg Thr Asp Leu Ser Thr Thr Val Ala Thr Pro Ser Ser Gly 3205 3210 3215 Leu Lys Lys Arg Pro He Ser Arg Leu Gin Thr Arg Lys Asn Lys Lys 3220 3225 3230 Leu Ala Pro Ser Ser Thr Pro Ser Asn He Ala Pro Ser Asp Val Val 3235 3240 3245 Ser Asn Met Thr Leu He Asn Phe Thr Pro Ser Gin Leu Pro Asn His 3250 3255 3260 Pro Ser Leu Leu Asp Leu Gly Ser Leu Asn Thr Ser Ser His Arg Thr 3265 3270 3275 3280 Val Pro Asn He He Lys Arg Ser Lys Ser Ser He Met Tyr Phe Glu 3285 3290 3295 Pro Ala Pro Leu Leu Pro Gin Ser Val Gly Gly Thr Ala Ala Thr Ala 3300 3305 3310 Ala Gly Thr Ser Thr He Ser Gin Asp Thr Ser His Leu Thr Ser Gly 3315 3320 3325 Ser Val Ser Gly Leu Ala Ser Ser Ser Ser Val Leu Asn Val Val Ser 3330 3335 3340 Met Gin Thr Thr Thr Thr Pro Thr Ser Ser Ala Ser Val Pro Gly His 3345 3350 3355 3360 Val Thr Leu Thr Asn Pro Arg Leu Leu Gly Thr Pro Asp He Gly Ser 3365 3370 3375 He Ser Asn Leu Leu He Lys Ala Ser Gin Gin Ser Leu Gly He Gin 3380 3385 3390 Asp Gin Pro Val Ala Leu Pro Pro Ser Ser Gly Met Phe Pro Gin Leu 3395 3400 3405 Gly Thr Ser Gin Thr Pro Ser Thr Ala Ala He Thr Ala Ala Ser Ser 3410 3415 3420 He Cys Val Leu Pro Ser Thr Gin Thr Thr Gly He Thr Ala Ala Ser 3425 3430 3435 3440 Pro Ser Gly Glu Ala Asp Glu His Tyr Gin Leu Gin His Val Asn Gin 3445 3450 3455 Leu Leu Ala Ser Lys Thr Gly He His Ser Ser Gin Arg Asp Leu Asp 3460 3465 3470 Ser Ala Ser Gly Pro Gin Val Ser Asn Phe Thr Gin Thr Val Asp Ala 3475 3480 3485 Pro Asn Ser Met Gly Leu Glu Gin Asn Lys Ala Leu Ser Ser Ala Val 3490 3495 3500 Gin Ala Ser Pro Thr Ser Pro Gly Gly Ser Pro Ser Ser Pro Ser Ser 3505 3510 3515 3520 Gly Gin Arg Ser Ala Ser Pro Ser Val Pro Gly Pro Thr Lys Pro Lys 3525 3530 3535 Pro Lys Thr Lys Arg Phe Gin Leu Pro Leu Asp Lys Gly Asn Gly Lys 3540 3545 3550 Lys His Lys Val Ser His Leu Arg Thr Ser Ser Ser Glu Ala His He 3555 3560 3565 Pro Asp Gin Glu Thr Thr Ser Leu Thr Ser Gly Thr Gly Thr Pro Gly 3570 3575 3580 Ala Glu Ala Glu Gin Gin Asp Thr Ala Ser Val Glu Gin Ser Ser Gin 3585 3590 3595 3600 Lys Glu Cys Gly Gin Pro Ala Gly Gin Val Ala Val Leu Pro Glu Val 3605 3610 3615 Gin Val Thr Gin Asn Pro Ala Asn Glu Gin Glu Ser Ala Glu Pro Lys 3620 3625 3630 Thr Val Glu Glu Glu Glu Ser Asn Phe Ser Ser Pro Leu Met Leu Trp 3635 3640 3645 Leu Gin Gin Glu Gin Lys Arg Lys Glu Ser He Thr Glu Lys Lys Pro 3650 3655 3660 Lys Lys Gly Leu Val Phe Glu He Ser Ser Asp Asp Gly Phe Gin He 3665 3670 3675 3680 Cys Ala Glu Ser He Glu Asp Ala Trp Lys Ser Leu Thr Asp Lys Val 3685 3690 3695 Gin Glu Ala Arg Ser Asn Ala Arg Leu Lys Gin Leu Ser Phe Ala Gly 3700 3705 3710 Val Asn Gly Leu Arg Met Leu Gly He Leu His Asp Ala Val Val Phe 3715 3720 3725 Leu He Glu Gin Leu Ser Gly Ala Lys His Cys Arg Asn Tyr Lys Phe 3730 3735 3740 Arg Phe His Lys Pro Glu Glu Ala Asn Glu Pro Pro Leu Asn Pro His 3745 3750 3755 3760 Gly Ser Ala Arg Ala Glu Val His Leu Arg Lys Ser Ala Phe Asp Met 3765 3770 3775 Phe Asn Phe Leu Ala Ser Lys His Arg Gin Pro Pro Glu Tyr Asn Pro 3780 3785 3790 Asn Asp Glu Glu Glu Glu Glu Val Gin Leu Lys Ser Ala Arg Arg Ala 3795 3800 3805 Thr Ser Met Asp Leu Pro Met Pro Met Arg Phe Arg His Leu Lys Lys 3810 3815 3820 Thr Ser Lys Glu Ala Val Gly Val Tyr Arg Ser Pro He His Gly Arg 3825 3830 3835 3840 Gly Leu Phe Cys Lys Arg Asn He Asp Ala Gly Glu Met Val He Glu 3845 3850 3855 Tyr Ala Gly Asn Val He Arg Ser He Gin Thr Asp Lys Arg Glu Lys 3860 3865 3870 Tyr Tyr Asp Ser Lys Gly He Gly Cys Tyr Met Phe Arg He Asp Asp 3875 3880 3885 Ser Glu Val Val Asp Ala Thr Met His Gly Asn Arg Ala Arg Phe He 3890 3895 3900 Asn His Ser Cys Glu Pro Asn Cys Tyr Ser Arg Val He Asn He Asp 3905 3910 3915 3920 Gly Gin Lys His He Val He Phe Ala Met Arg Lys He Tyr Arg Gly 3925 3930 3935 Glu Glu Leu Thr Tyr Asp Tyr Lys Phe Pro He Glu Asp Ala Ser Asn 3940 3945 3950 Lys Leu Pro Cys Asn Cys Gly Ala Lys Lys Cys Arg Lys Phe Leu Asn 3955 3960 3965 Glx (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..51 (D) OTHER INFORMATION: /product= "Genomic nucleotide sequence encoding ORFl" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: TTC TTT AAC AGA CAA TGC ATC AAT TGC TGG CTC AGA AGA TGC ATG ACC 48 Phe Phe Asn Arg Gin Cys He Asn Cys Trp Leu Arg Arg Cys Met Thr 1 5 10 15 AGC 51 Ser (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: Phe Phe Asn Arg Gin Cys He Asn Cys Trp Leu Arg Arg Cys Met Thr 1 5 10 15 Ser ( 2 ) INFORMATION FOR SEQ ID NO: 8 : ( i ) SEQUENCE CHARACTERISTICS : (A) LENGTH : 17 amino acids ( B ) TYPE : amino acid (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: Phe Tyr Lys Asp Arg Cys Thr Ala Cys Trp Leu Lys Lys Cys Met He 1 5 10 15 Ser (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 amino acids (B) TYPE: amino acid (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: Asp Glu Met Tyr Glu He Leu Ser Asn Leu Pro Glu Ser Val Ala Tyr 1 5 10 15 Thr Cys Val Asn Cys Thr Glu Arg 20 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 amino acids (B) TYPE: amino acid (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: Asp Glu Gin Tyr Asn Leu Leu Ser Thr Leu Pro Glu Ser He Glu Phe 1 5 10 15 He Cys Lys Lys Cys Ala Arg Arg 20 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 77 amino acids (B) TYPE: amino acid (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: Asp Phe Ser Leu Cys His Asp Cys Ala Lys Leu Phe Ala Lys Gly Asn 1 5 10 15 Phe Cys Pro Leu Cys Asp Lys Cys Tyr Asp Asp Asp Asp Tyr Glu Ser 20 25 30 Lys Met Met Gin Cys Gly Lys Cys Asp Arg Trp Val His Ser Lys Cys 35 40 45 Glu Asn Leu Ser Asp Glu Met Tyr Glu He Leu Ser Asn Leu Pro Glu 50 55 60 Ser Val Ala Tyr Thr Cys Val Asn Cys Thr Glu Arg His 65 70 75 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 77 amino acids (B) TYPE: amino acid (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: Asn Leu Pro Met Cys Thr Gly Cys Phe Lys Leu Arg Lys Lys Gly Asn 1 5 10 15 Phe Cys Pro He Cys Gin Arg Cys Tyr Asp Asp Asn Asp Phe Asp Leu 20 25 30 Lys Met Met Glu Cys Gly Asp Cys Gly Gin Trp Val His Ser Lys Cys 35 40 45 Glu Gly Leu Ser Asp Glu Gin Tyr Asn Leu Leu Ser Thr Leu Pro Glu 50 55 60 Ser He Glu Phe He Cys Lys Lys Cys Ala Arg Arg Asn 65 70 75

Claims: That which is claimed is: 1. An isolated peptide having the characteristics of human trithorax protein. 2. A peptide according to claim 1 wherein said peptide has a DNA binding domain comprising multiple zinc fingers and at least 40% amino acid identity with respect to the DNA binding domain of Drosophila trithorax protein and at least 70% conserved sequence with respect to the DNA binding domain of Drosophila trithorax protein, and wherein said peptide is encoded by a gene located at chromosome 11 of the human genome at q23. 3. A peptide according to claim 1 having substantially the same sequence as set forth in SEQ ID NO:2. 4. Isolated nucleic acid encoding the peptide of claim 1, or nucleic acid capable of hybridizing therewith under low stringency hybridization conditions. 5. Nucleic acid according to claim 4 wherein said nucleic acid is DNA. 6. DNA according to claim 5 having substantially the same sequence as set forth in SEQ ID NO:1, or DNA capable of hybridizing therewith under low stringency hybridization conditions. 7. Antisense nucleic acid complementary to the nucleic acid of claim 4. 8. A method for the treatment of a subject suffering from immunodeficiency, developmental abnormality, inherited disease, or cancer, said method comprising administering to said subject a therapeutically effective amount of the peptide of claim 1. 9. A method for the treatment of a subject suffering from immunodeficiency, developmental abnormality, inherited disease, or cancer, said method comprising administering to said subject a therapeutically effective amount of an antagonist to the peptide of claim 1. 10. A method for the treatment of a subject suffering from immunodeficiency, developmental abnormality, inherited disease, or cancer, said method comprising administering to said subject an effective amount of the antisense nucleic acid of claim 7. 11. A method for the diagnosis, in a subject, of immunodeficiency, developmental abnormality, inherited disease, or cancer associated with disruptions of chromosome 11 at q23, said method comprising analyzing biological material obtained from said subject for evidence of a defect in the gene encoding human trithorax peptide. 12. A method according to claim 11 wherein said evidence of a defect in the gene encoding human trithorax peptide is the occurrence of a translocation which results in disruption of said gene. 13. A method according to claim 11 wherein evidence of a defect in the gene encoding human trithorax peptide is obtained by PCR amplification of a portion of the gene encoding human trithorax peptide using PCR primers derived from unique sites located both centromeric and telomeric of the translocation breakpoint. 14. A method according to claim 13 employing as primer any sequence of at least 15 contiguous nucleotides, or complements thereof, selected from nucleotide 1 - 11,907 as set forth in Sequence ID No. 4. 15. A method according to claim 11 wherein said evidence of a defect in the gene encoding human trithorax peptide is obtained by hybridization of DNA derived from wild-type human trithorax gene region to a Southern blot of DNA obtained from said subject. 16. A method according to claim 11 wherein said evidence of a defect in the gene encoding human trithorax peptide is obtained by in situ hybridization of DNA derived from wild-type human trithorax peptide to DNA obtained from said subject. 17. Method for determining, in a subject, the presence of, or susceptibility to, disease states associated with disruption of chromosome 11 at q23, said method comprising: (a) hybridizing intact chromosomal DNA from said subject with at least one probe specific for chromosome llq23, and (b) identifying intact chromosomal DNA which has a different pattern of hybridization, relative to the pattern of hybridization of said probe with intact chromosomal DNA free of any aberrations, said identification being indicative of the presence of, or susceptibility to, disease states associated with disruption of chromosome 11 at q23. 18. A method according to claim 17 wherein said at least one probe specific for chromosome llq23 is selected from cosmid cl08, cll6, c4 or plasmid p4.3. 19. A method according to claim 17 wherein the presence of a disease state associated with disruptions of chromosome 11 at q23 is distinguished from the presence of other disease states. 20. A probe having substantially the same sequence as the unique 110, 120 or 180 nucleotide sequences contained in SEQ ID NO:l.

Inventors: DJABAKI MALEK, EVANS GLEN A, PARRY PAULINE, SELLERI LICIA, DJABAKI, MALEK, EVANS, GLEN, A., PARRY, PAULINE, SELLERI, LICIA
Applicants: SALK INST FOR BIOLOGICAL STUDI, THE SALK INSTITUTE FOR BIOLOGICAL STUDIES
Application year: 1993
Main classification: A61K31
IPC codes: A61K38, C07K14, C12Q1